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Part One  
General Introduction 
 
Skin is the largest organ of the human body, which interfaces with the 
environment and covers a surface area between 1.5 and 2.0 m2. From a 
pharmaceutical point of view, skin offers a glorious route for delivering drugs because 
skin drug delivery brings forth many attractive advantages over other routes of 
administration, including avoidance of first-pass metabolism, sustained and controlled 
delivery over a prolonged period of time, reduction in side effects associated with 
systemic toxicity, improved patient acceptance and compliance, direct access to target 
or diseased site, convenient and painless administration and so on (Brown et al., 2006).  
On the other hand, however, skin is also an excellent biological barrier, which is 
as much as 102-104 times less permeable than a blood capillary wall (Cevc and Vierl, 
2010) and imposes physicochemical limitations to the type of permeants which can 
traverse it. For a drug to be delivered successfully and passively into or through the 
skin, small molecular size (ideally a molecular weight less than 500Da) and sufficient 
aqueous and lipid solubility (a LogPoctanol/water between 1 and 3) are essential and 
required (Yano et al., 1986). In addition, the presence of enzymes in the skin such as 
peptidases and esterases might metabolize the drug into a form which could be 
therapeutically inactive, thereby reducing the efficacy of the drug (Steinstrasser and 
Merkle, 1995). Moreover, skin irritation and sensitization provoked by exposure to 
certain stimuli such as drugs, excipients or any other component of topical 
formulations could also be a limitation to the product on market (Carmichael, 1994; 
Hogan and Maibach, 1990; Toole et al., 2002). Thus, all of these requirements 
mentioned above, at least, have limited the number of commercially available 
products based on skin delivery.  
Over the past decades, numerous studies have been performed to overcome the 
problems associated with skin delivery and also a number of novel skin delivery 
systems and approaches have been developed, including the use of chemical 
penetration enhancers(Goodman and Barry, 1988; Williams and Barry, 2004), 
modifying chemical potential of the drug (Megrab, 1995), the application of 
liposomes and other colloidal drug carrier systems, electrically driving molecules into 
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or through the tissue employing iontophoresis (Miller et al., 1990), or physically 
disrupting the skin structure by electroporation or sonophoresis (Prausnitz et al., 
1993a; Prausnitz et al., 1993b) and others (Nanda A, 2006). Among these novel 
techniques, lipid vesicular systems such as conventional liposomes, deformable 
liposomes (transfersomes), and ethosomes may offer a promising strategy for 
successfully improving skin drug delivery.  
1 The Aim of Research  
As mentioned, skin is known to exhibit selective permeability with respect to the 
type of diffusing molecules. In fact, the ability of each drug to penetrate into the skin 
and the diffusion route it takes are dependent on its own physicochemical properties 
and the interactions it has with the skin’s various conduit regimes (Lu and Flynn, 
2009). When it comes to liposomal drug carrier systems, the situation could be more 
complicated. Firstly, encapsulated drug could be located at different position 
according to their lipophilicity. For instance, lipophilic drugs could be incorporated 
into the bilayers; while the hydrophilic one could be loaded within the water phase 
inside the vesicles and could be also found outside the liposomes in high amounts. 
This could affect the interaction between drugs and lipid carrier systems and in turn 
influence the penetration and deposition behavior of drugs. Moreover, the function of 
liposomal systems varies with type and composition. For instance, liposomal systems 
may act as drug carriers controlling release of the medicinal agent. They may also 
provide a localized depot in the skin so minimizing systemic. Alternatively, liposomes 
may enhance transdermal drug delivery, increasing systemic drug concentrations. In 
addition, liposomal systems can also be used for targeting delivery to skin appendages.  
Thus, how the fate of drugs could be changed by different liposomal systems? 
More specifically, do the liposomal systems enhance drug deposition into the skin? Or 
do they enhance drug transport across the skin? Or do they enhance both dermal and 
transdermal delivery? Moreover, the compositions of liposomal systems could change 
due to penetration into the skin or evaporation of volatile components. These changes 
depend on the amount of liposome applied and occlusion conditions. And these 
differences may result in variations in the effects of liposomal systems as skin drug 
delivery tools. Hence, do application mode and the amount of liposomes applied have 
an impact on their effectiveness as skin drug delivery tools? At last but not the least, 
what are reasonable mechanisms of different liposomal systems to deliver therapeutic 
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agents to and through the skin at each specific situation?   Therefore, the aims of the 
whole study are as following: 
1)  Development of different lipid vesicular systems containing different model 
drugs, including conventional liposomes, deformable liposomes (invasomes) and 
ethosomes. 
2) Characterization of lipid vesicular systems, including particle size distribution, 
zeta potential, lamellarity and particle shape.  
3) Investigate the percutaneous absorption of model drugs via different lipid 
vesicular systems as well as the effect of application mode on this process.  
4) Analysis of results and discussion on the reasonable mechanisms of action of 
different lipid vesicular systems when topically applied. 
Furthermore, in order to better understand all these questions mentioned above, 
one must be knowledgeable about the anatomical structure and chemical compositions 
of skin, the skin barrier function and penetration routes, formulation considerations 
for skin drug delivery, the classification and potential compositions of different 
liposomal systems as well as their topical application, and so on. Therefore, all of 
these would be the subjects for discussion in this chapter. Rational considerations to 
skin drug delivery via liposomal systems rest on having such insights in advance. 
2 The Structure of Skin  
Skin is anatomically divided into three principal and distinct layers, from the 
outside of skin inward, including stratum corneum (10–20 µm thick), viable epidermis 
(50–100 µm thick), and dermis (1000-2000 µm thick). A fatty subcutaneous layer 
resides beneath the dermis. It should be pointed out that all the thickness specified 
here are representative only, since the actual thickness of each layer varies several 
fold from place to place on the body. Adnexal appendages, including hair follicles, 
associated sebaceous glands and pili muscles, apocrine and eccrine sweat glands, can 
be found dispersing throughout of the skin, varying in number and size depending on 
body site. The cross section of skin structure is shown is Figure 1. 
2.1 Stratum Corneum 
Stratum corneum is the outmost superficial layer of the skin and also the 
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principal barrier element of the skin. SC consists of several layers of completely 
keratinized flattened dead cells, corneocytes, each of which is about 30 µm in 
diameter with a hexagonal shape and 0.5-0.8 µm in thickness (Holbrook and Odland, 
1974). These acutely flattened corneocytes are highly organized and stacked vertically 
15 to 25 cell layers, which are embedded into a specialized and well structured 
intercellular lipid matrix (Wertz et al., 1989).  
 Fig.1 A cross sectional view of human skin, Source: From Ref. (Lu and Flynn, 2009) 
The most simplistic organizational description of SC is advocated by Elias (Elias, 
1987, 1989; Williams and Elias, 1993), which is the classic “brick-and-mortar” 
assembly (Figure 2). The intracellular space of corneocytes is literally packed with 
structural protein, semi crystal line α keratin intermixed with more amorphous β 
keratin. The intracellular space is dense, offering little freedom of movement to drug 
molecules. Thus, the corneocytes work as “brick” being thermodynamically 
impenetrable. While the intercellular space of corneocytes is filled with a lipid 
“mortar” formed of cholesterol, free fatty acids, and ceramides, which seals horny 
structure (Figure 2).   
However, the brick-and-mortar skin model is not enough to describe the 
panorama of the SC. In fact, the cells from basal layer of epidermis, which we 
describe further in the text, to the SC are built up in clusters, which represent the basic 
skin permeation resistance unit (Cevc, 2004). It is these clusters that are separated by 
surface corrugations (wrinkle line), which often reach several micrometers into the 
basal layer of the epidermis (Figure 3).    
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Fig.2 Brick-and-mortar model of Stratum 
corneum and penetration routes through it, 
Source from Ref. (Elias, 1981) 
Fig.3 Epidermis with Stratum corneum, 
including a corneocytes cluster, Source from 
Ref. (Cevc and Vierl, 2010) 
In addition, the basolateral side of stratum corneum is in direct contact with the 
living epidermal mass, where the corneocytes contain water at high thermodynamic 
activity of the physiological milieu. On the other hand, its external surface interfaces 
the environment, where air tends to have a far lower water activity. Consequently a 
water gradient is established and water diffuses out through the stratum corneum. 
Under such a normal hydration situation, the stratum corneum takes up moisture to 
the extent of 15% to 20% of its dry weight (Lu and Flynn, 2009). It should be pointed 
out here that the hydration condition of SC plays an important role on the drug 
molecules skin penetration, which would be discussed further in the text. 
2.2 Viable Epidermis 
The viable epidermis is underlying the stratum corneum. It is multilayered when 
viewed under microscope, including, from bottom to top, basal layer (stratum 
germinativum), spinous layer (stratum spinosum), granular layer (stratum granulosum) 
and lucid layer (stratum lucidum). Each layer is defined by position, shape, and 
morphology and also reflects the progressive differentiation of keratinocytes which 
eventuates into their death and placement as chemically and physically resistant 
“brick” in stratum corneum. However, when physicochemically considered, the viable 
epidermis is just a group of tightly massed live cells, which results in a singular 
diffusion area or resistance in percutaneous absorption process. Water found in this 
live epidermis has an activity equivalent to that of 0.9% NaCl (Lu and Flynn, 2009). 
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While the interface between stratum corneum and epidermis is flat, the one 
between epidermis and dermis is papillose, which increases their contact surface area 
and then allows for the diffusion of nutrients or other biological or medicated 
molecules between dermis and epidermis (Figure 1). The epidermis itself is avascular.  
Besides keratinocytes, Langerhans cells also can be found in viable epidermis. 
They are antigen presenting cells in the skin’s immunological responses. Moreover, 
another kind of cells, melanocytes, are strategically placed in the epidermis just above 
the epidermis and dermis junction. When influenced by melanocyte-stimulating 
hormone or ultraviolet radiation, melanocytes synthesize and deposit the pigment 
granules into skin, which gives rise to the skin coloration.  
 
2.3 Dermis 
Dermis is directly adjacent to the epidermis and extends from the epidermal-
dermal junction to the subcutaneous tissue (Figure 1).  Dermis consists of a net-work 
of irregular connective tissue, which provides the mechanical support for the skin. 
The matrix of this connective tissue consists of structure fibers, such as collagen, 
reticulum, and elastin. These fibers are embedded in an amorphous 
mucopolysaccharidic gel called the ground substance (Lu and Flynn, 2009). The 
dermis can be arbitrarily divided in into a superficial papillary layer and a deep 
reticular layer. The upper papillary layer is thin, one fifth of thickness of the dermis, 
and protrudes in to the epidermis giving rise to the dermal papilla, and also provides 
the support of the delicate capillary plexus which nurtures the epidermis. The deepest 
layer of the skin is a far coarser fibrous matrix, the reticular dermis, which is the main 
structural element of the skin. Equally importantly, the microcirculation which 
subserves the skin is entirely housed in the dermis. Blood flow through skin can vary 
by a factor of 100 fold depending on environmental conditions. The dermis is also 
penetrated by sensory nerve endings and an extensive lymphatic network.  Moreover, 
skin appendages such as sweat gland, sebaceous glands, hair follicles, and arrector pili 
muscles are anchored within the dermis.   
The main cell inhabitants of the dermis are fibroblasts, mast cells and 
macrophages. Fibroblasts synthesize the structural fibers, while mast cells are thought 
to synthesize the ground substance. Macrophages work as immune response. In 
addition, plasma cells, chromatophores, fat cells, nerve cells and endings can also be 
found along with blood vessels, nerves and lymphatics.  
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2.4 Skin Appendages 
Skin appendages include hair follicles and their associated sebaceous glands, 
eccrine glands, apocrine glands, and arrector pili muscles.  
The hair follicle unit is composed of the hair, hair follicle, associated sebaceous 
gland, and pili muscles. Hair is a compact of keratinized structures, which consist of 
three layers, including an outermost cuticle, a cortex of densely packed keratinized 
cells, and a medulla of loose flattened cells.  Hairs can be found mostly everywhere 
on the body except for the soles of the feet, the palms of the hand, and mucocutaneous 
junctions. There are100 follicles per square centimeter, representing one thousandth of 
the skin’s surface. A hair emerges from a follicle, which is set within the dermis at a 
slight angle. The hair follicle consists of three major components, including internal 
root sheath, external root sheath, and dermal papilla (Figure 4). This arrangement 
results in a solid implantation of the hair root in the hair follicle. In addition, each 
follicle is anchored to the surrounding connective tissue by an individual strand of 
arrector pili muscle. Furthermore, each follicle is associated with one or more flask 
like sebaceous glands, which secret an oily secretion, sebum. Then the sebum is 
forced upward around the hair shaft and onto the skin surface. Sebum mainly consists 
of squalene, cholesterol esters, wax esters, and triglycerides. It has several biological 
functions including the regulation of steroidogenesis and androgen synthesis, and 
providing antibacterial and water resistance to skin.  
 
Fig.4 Skin appendages: (a) Structure of the skin (b) Structure of the hair follicle 
(c) Cross-section of the hair, source from Ref. (Wosicka and Cal, 2010) 
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Eccrine glands (sweat glands) are distributed over the entire body except the genitalia 
and lips. These simple tubular glands open directly on the skin surfaces and extend to 
the footings of the dermis. There are between 150 and 600 glands per square 
centimeter of body surface depending on body site (Lu and Flynn, 2009). However, 
the estimated number of actual sweating glands is much less than that value, since 
many of these glands remains dormant. Thus, these glandular openings occupy 
approximately one ten thousandth of the skin surface. Eccrine sweat is slightly acidic 
(pH=5) due to traces of lactic acid, which is moderately bacteriostatic. 
2.5 Skin circulatory system 
Skin circulatory system not only provides nutrients to the skin, hair follicles, the 
glandular appendages as well as the subcutaneous fat, but also participates in other 
biological functions, such as heat exchange, repair, and immune responses. Skin 
circulatory system is an extensive vascular network. The blood supply to the skin 
arises from substantial arteries which are located in the subcutaneous connective 
tissue. The terminal branches of these arteries in turn give rise to three plexuses: (i) 
subcutaneous plexus, which is located just beneath the dermis and gives off the 
branches to the (J du Plessis) cutaneous plexus, which brings a blood supply into 
dermis with reaching the upper dermis and then further branches to form (iii) the 
shallower subpapillary plexus of capillary loops which bring a blood supply up into 
the papillae at the dermal epidermal interface. The transport of nutrients into 
epidermis or substance exchange between epidermis and dermis is achieved via 
passive diffusion. The epidermis itself is avascular. The veins into skin are organized 
along the same lines as the arteries (Lu and Flynn, 2009), in which there are also three 
plexus including subcutaneous plexus, cutaneous plexus and subpapillary plexus.  It 
should be pointed out that arterioles belonged to cutaneous plexus and subpapillary 
plexus exhibit arteriovenous anastomoses, which are shunt like connections that link 
the arterioles directly to corresponding venules (Lu and Flynn, 2009).  
The vascular surface available for exchange of substances including drugs 
between the blood and the local tissue has been estimated to be of the same magnitude 
of that of the skin. The blood flow through the skin is reported from 0.01 up to 1 ml 
per minute per gram of tissue, which depends on the body site and temperature. 
Sufficient blood to within 150μm of the skin’s surface efficiently draws chemicals 
into the body that has gained access to this depth (Lu and Flynn, 2009).   
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3 Skin Penetration Routes 
When a skin drug delivery system is applied topically, drug-containing carriers 
or free drug in the system could interact with either the stratum corneum or the sebum 
filled ducts of the pilosebaceous glands. Thus, two principle absorption routes are 
involved, including the transepidermal route, where the drug delivery system interacts 
with or diffuses through stratum corneum, and transfollicular route, where they 
interact with or diffuse through the follicles.  
In the case of the transepidermal route, since the impermeable character of the 
corneocytes, the intercellular space of corneocytes provides the only continuous phase, 
which is also the predominant penetration pathway (intercellular route or 
intercorneocyte pathway) from the skin surface to the viable epidermis. However, the 
tortuous zigzag bestowed by staggered corneocytes arrangement (typically 18–21), 
corneocyte layers (Menon, 2002), as well as the highly organized crystalline lamellae 
structures of the mortar lead to an outstanding barrier property of the labyrinthine 
intercellular route. The transportation of molecules across this layer is primarily 
passive diffusion, in accordance with Fick’s law, and no active transport processes 
have been identified to date (Brown et al., 2006). Thus the permeability of stratum 
corneum as a penetration resistor is proportional to the diffusive mobility of drug 
molecules within it (diffusion coefficient, Dsc, also proportional to the capacity of the 
SC to solubilize the drug molecules relative to vehicle (partition coefficient, Ksc) but 
inversely proportional to the thickness of stratum corneum (hsc). Consequently, at the 
steady state and sink condition, drug permeation can be described as following: 
ܬ௦௖ ൌ
௄ೞ೎஽ೞ೎஼
௛ೞ೎
                                                                   (1) 
 
where Jsc (µg cm-2 h-1) is the steady state flux through stratum corneum. C is the 
concentration of drug in the topical drug delivery system.  
When considering transfollicular route, initially it was not considered to be a 
significant skin penetration route, as evidence suggested that they accounted for only 
approximately 0.1% of the skin surface area (H.Schaefer and Redelmeier, 1996). 
Recently, it has been demonstrated that hair follicles may act as a significant 
penetration pathway and/or potential reservoirs for topically applied compound 
(Blume-Peytavi et al., 2010; Grice et al., 2010; Lademann et al., 2010; Lademann et 
al., 2006).  As mentioned before, owing to the presence of sebum in follicles, the 
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permeation through follicular route can be described as following: 
ܬ௦௘௕௨௠ ൌ
௄ೞ೐್ೠ೘஽ೞ೐್ೠ೘஼
௛ೞ೐್ೠ೘
                                                  (2) 
 
where Jsebum (µg cm-2 h-1) is the steady state flux through sebum/hair follicle. C is the 
concentration of drug in the topical drug delivery system. Ksebum and Dsebum are 
diffusion coefficient through sebum and drug partition coefficient in sebum/water, 
respectively. 
In short, either or both routes can be important depending on the 
physicochemical properties of a drug as well as the condition of the skin, since the 
percutaneous absorption is a spontaneous passive diffusion process which takes the 
path of least resistance. 
4 Liposomal Systems for Skin Drug Delivery 
Liposomes were introduced in 1965 by Bangham et al (Bangham et al., 1965). 
Initially, they were used as a model for membrane system studies. However, the 
topical application of liposomal systems has attracted increasing attention in 
dermatology since the first liposomal product, which was an econazole preparation for 
topical therapy of dermatomycosis, introduced into the market in 1988. 
Essentially, liposomal vesicles are colloidal particles in which one or more lipid 
bilayers entrap an aqueous volume. Their major components are usually 
phospholipids, with or without some additives. There are a wide variety of lipids and 
additives that can be used to prepare these vesicles. Phospholipids could 
spontaneously aggregate into vesicular structure after addition of water, which results 
from their amphipathic character due to the presence of a polar or hydrophilic (water-
attracting) head-group region and a non-polar, lipophilic (water-repellent) tail. The 
hydrophilic head groups orientate toward the aqueous phase and the lipophilic tails 
orientate to each other in the presence of water (Fig. 5) (Hope and Kitson, 
1993).Therefore, liposomes contain a lipophilic compartment within the bi-layer 
membranes and hydrophilic compartments between the membranes. Correspondingly, 
lipophilic drugs could be incorporated into the bilayers; while the hydrophilic one 
could be loaded within the water phase inside the vesicles and could be also found 
outside the liposomes in high amounts (Weiner et al., 1994).  
Liposomes can be classified according to their particle size. Small unilamellar 
vesicles (SUV) have dimensions of 20 up to about 50 nm. Large unilamellar vesicles 
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(LUV) are between 50 and 500 nm, and multilamellar vesicles (MLV) have 
dimensions exceeding 500 nm but below 10,000 nm in diameter. SUVs are less 
suitable for drug delivery because they lack stability and their volume is too small for 
entrapping drugs. And generally, the penetration of liposomes through the stratum 
corneum decreases with increasing diameters. Therefore, the preferred structures for 
drug delivery are liposomes that are 50–500 nm in diameter (Hope and Kitson, 1993). 
 
 
Figure 5 Top left structural formula of the phosphatidylcholine molecule. In the presence of water 
phospholipid bilayers are formed, which create vesicles, enclosing an aqueous core. Lipid soluble 
substances can be stored in the outer lipid phase (yellow ring) and water soluble substances in the inner 
aqueous phase (blue centre). Source from Ref. (de Leeuw et al., 2009) 
 
Another essential characteristic of liposomes for penetration through the stratum 
corneum is their state in a liquid crystal phase. The lipid bi-layer passes from a gel 
into a liquid crystal phase at a critical phase transition temperature (cptT). At the cptT, 
the head groups become fully hydrated and the lipid chains become freely mobile in 
the membrane. Phosphatidylcholine can form bi-layers at cptT below room 
temperature. This liquid crystal state is essential for liposomes to interact 
simultaneously with the lipid and the aqueous compartments of the stratum corneum, 
and for delivering entrapped drugs into the skin (de Leeuw et al., 2009).  
Liposomes also can be classified according to their components. Most commonly, 
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the vesicles only composed of phospholipids, with or without cholesterol, can be 
called conventional liposomes. Since the first liposome based topical formulation 
available in the market, shortly afterwards, several other conventional liposome 
formulations for dermal delivery of local anesthetic, antifungal, anti-inflammatory 
and anticancer drugs were developed and produced (Sinico and Fadda, 2009). All 
these conventional liposomes carry drugs mainly targeted to the dermal region of the 
skin (Sinico and Fadda, 2009). In 1992, Cevc and Blume (Cevc and Blume, 1992) 
introduced the deformable liposomes, referred to as Transfersomes® (IDEA AG, 
Munich, Germany). And recently Fahr and colleagues developed invasomes 
(Dragicevic-Curic et al., 2008; Verma, 2002), composed of phosphatidylcholine, 
ethanol and a mixture of terpenes as penetration enhancers. All these vesicles contain 
additional edge activators such as surfactants and lysophosphatidylcholine (LPC) to 
modify the bilayer elasticity and to increase deformability. Because of their elasticity 
and deformability, they seem to be a useful carrier for transdermal delivery of some 
drugs (Elsayed et al., 2007b). The effectiveness of deformable liposomes as both 
dermal and transdermal delivery systems has been successfully demonstrated by using 
numerous chemical agents of different molecular sizes and lipophilicity, such as 
lidocaine, tetracaine, cyclosporin, hydrocortisone, dexamethasone, triamcinolone 
acetonide, diclofenac, ibuprofen, tamoxifen, testosterone, etc. (Cevc, 1997). Another 
kind of liposomal vesicle are ethosomes, which are also composed of phospholipids 
but embodying a high concentration (20–45%) of alcohol (ethanol or isopropyl 
alcohol). Ethosomes too can penetrate the skin and improve dermal, transdermal 
delivery of a lot of drugs, including highly lipophilic molecules and cationic drugs 
such as acyclovir, trihexyphenidyl, minoxidil, cannabinoids, zidovudine, and 
testosterone through the skin (Godin and Touitou, 2003; Nanda A, 2006; Touitou et al., 
2000). Pharmaceutical formulations based on ethosomes technology have been 
developed by Novel Therapeutic Technology, Inc., for the treatment of several 
diseases (i.e., alopecia, erectile dysfunction, dermatitis) by topical application of 
drugs (Sinico and Fadda, 2009). 
In short, it is believed that the topical use of lipid vesicles can support various 
medical applications because their delivery enhancing properties could be modulated 
by changes in composition and structure. Moreover, lipid vesicles also provide a 
promising approach aiming at both increasing efficiency and reducing toxicity of 
drugs with topical application. 
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Part Two 
Publication Overview 
 
1. Book Chapter: Liposomes as Promising Tools for the Skin Delivery and 
Protection of Damaged Skin. Alfred Fahr and Ming Chen. Toxicology of the 
Skin, Monteiro-Riviere, N.A. (Ed.), First ed. 2010, Informa Healthcare. 
 
Abstract: Application of lipid vesicular formulations as transdermal delivery systems 
in order to enhance drug transport across the skin barrier is one of the most 
controversial technologies, which was expounded in this review, with a special 
emphasis on the effectiveness of these liposomal systems as skin drug delivery 
systems. On the other hand, the significance of the skin and fascinating functions it 
performs cannot be overstated. Thus, any breach in the integrity of the skin or any 
compromised function will have a profound effect so that the protection of damaged 
skin cannot be neglected, which will be discussed at length in this review. 
 
Own contribution to the manuscript: 
Review of liposomal vesicles as transdermal drug delivery, including conventional 
liposomes, deformable liposomes and ethosomes.  
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2. Research Paper: Skin Delivery of Ferulic Acid from Different Vesicular 
Systems. Ming Chen, Xiangli Liu and Alfred Fahr. Journal of Biomedical 
Nanotechnology Vol. 6, 1̢9, 2010. 
 
Abstract: Different lipid vesicular systems were designed and prepared in order to 
improve skin delivery of ferulic acid which is a traditional Chinese medicine (TCM) 
exhibiting a wide range of therapeutic effects against various diseases. All test 
formulations were characterized for particle size distribution, ζ-potential, vesicular 
shape and surface morphology. Furthermore, the skin delivery capabilities of different 
vesicular systems were investigated with in vitro human skin permeation and skin 
deposition study, indicating that well developed lipid vesicles are promising vesicular 
carriers for delivering ferulic acid into or across the skin. 
 
Own contribution to the manuscript: 
1) Preparation and characterization of different lipid vesicular systems, including 
conventional liposomes, Tween 80-based deformable liposomes, invasomes and 
ethosomes 
2) Preparation of stratum corneum/epidermis (SCE) membranes and establishment 
of fluorescent assay of ferulic acid 
3) Performance of in vitro skin permeation and deposition studies of all lipid 
vesicular formulations  
4) Data evaluation, and interpretation and representation of the results 
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3. Research Paper: Skin penetration and deposition of Carboxyfluorescein and 
Temoporfin from different lipid vesicular systems: In vitro study with finite 
and infinite dosage application. Ming Chen, Xiangli Liu and Alfred Fahr. 
International Journal of Pharmaceutics, Submitted. 
 
Abstract: Different lipid vesicular systems containing Carboxyfluorescein 
(hydrophilic model drug) or Temoporfin (lipophilic model drug) were prepared in 
order to evaluate the influence of different lipid vesicular systems on their skin 
penetration and deposition behaviors. All test formulations were characterized for 
particle size distribution, ζ-potential, vesicular shape and surface morphology. 
Furthermore, the effect of different application modes, including application of finite 
dosage and infinite dosage, on skin penetration and deposition were investigated. All 
the results revealed that the factors influencing the drug skin distribution concern the 
physicochemical characteristics of the drug, the choice of the vehicle formulation and 
the application mode applied. 
 
Own contribution to the manuscript: 
1) Preparation and characterization of different lipid vesicular systems containing 
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INTRODUCTION
The significance of the skin and fascinating functions it performs, such as pro-
tection, sensation, heat regulation, control of evaporation, absorption, storage
and synthesis, water resistance, and so on, cannot be overstated. Because of
limited space, this chapter will not provide detailed information on all aspects of
skin function. However, more information may be accessible from other chap-
ters in this book (see chap. 1) and from other literature (1–3). Furthermore, on
account of the demonstrated importance of skin, any breach in the integrity of
the skin or any compromised function will have a profound effect so that the
protection of damaged skin cannot be neglected, which will be discussed at
length in this chapter.
On the other hand, skin covers a surface area between 1.5 and 2.0 m2 and is
often regarded as the largest organ of the human body. From a pharmaceutical
point of view, it offers a glorious route for delivering drugs because transdermal
drug delivery brings forth many attractive advantages over other routes of
administration, including avoidance of first-pass metabolism, lower fluctuations
in plasma drug levels, and good patient compliance (4). According to a report by
Jain PharmaBiotech, the value of the global market for transdermal drug
delivery was $12.7 billion in 2005 and is expected to increase to $21.5 billion in
2010 and $31.5 billion in 2015. The transdermal drug delivery market is about to
soar and become an indispensable contributor within the pharmaceutical
industry.
However, every coin has two sides, for the pharmaceuticals, the skin is
also a tough barrier for delivering drugs. The first commercial transdermal
product was made available in the global transdermal market in the early 1980s,
and there are only 11 approved molecules utilizing transdermal technology
introduced over past two decades that includes scopolamine, nitroglycerin,
clonidine, estradiol, fentanyl, nicotine, testosterone, norethisterone, lidocaine,
oxybutynin, and methylphenidate (5). The major reason for so few drugs is the
low permeability of drugs in the stratum corneum (SC), the outermost layer of
the skin that acts as the primary barrier (6). Numerous techniques have been
employed to overcome the barrier posed by the SC to improve transdermal drug
delivery. One of the most controversial technologies is the employment of lipid
vesicular formulations as transdermal delivery systems to enhance drug trans-
port across the skin barrier. This will be expounded in this chapter, with a
special emphasis on the effectiveness of these liposomal systems as skin drug
delivery systems.
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LIPOSOMAL SYSTEMS AS A TOOL FOR TRANSDERMAL
DRUG DELIVERY
Skin Barrier and Penetration Pathways
Anatomically, the skin consists of three distinct layers, including SC (10–20 mm
thick), viable epidermis (50–100 mm thick), and dermis (1–2 mm thick). As
mentioned above, the skin’s barrier function is accomplished by the outermost
layer of the skin, the SC (see chap. 1).
The most simplistic organizational description of SC is advocated by Elias
(7) (see chap. 2), which is the classic “brick-and-mortar” assembly. This structure
is analogous to a wall that is composed of corneocytes (brick, because of the
cornified envelope around each corneocyte) embedded in a bilayer lipid mem-
branes matrix (mortar) formed of cholesterol, free fatty acids, and ceramides (6).
Importantly, the “mortar” provides the only continuous phase, which is also the
predominant penetration pathway (intercellular route or intercorneocyte path-
way), from the skin surface to the viable epidermis. However, the impermeable
character of the “brick” and the tortuous zigzag bestowed by staggered cor-
neocyte arrangement (typically 18–21), corneocyte layers (8), as well as the
highly organized crystalline lamellae structures of the mortar lead to an out-
standing barrier property of the labyrinthine intercellular route. The transpor-
tation of molecules across this layer is primarily passive diffusion, in accordance
with Fick’s law, and no active transport processes have been identified (4) to
date. Moreover, the SC is very selective with respect to the type of diffusing
molecules, which means the barrier nature of the skin imposes physicochemical
limitations to the type of permeants that can traverse the skin, including
hydrophilicity, size, and hydrogen-bonding ability (9–11). As a consequence, all
of these factors are responsible for the high transport resistance of the inter-
cellular penetration route.
On the other hand, the brick-and-mortar skin model is not enough to
describe the panorama of the SC. In fact, the cells from basal layer of epidermis to
the SC are built up in clusters, which represent the basic skin permeation resistance
unit (12). It is these clusters that are separated by surface corrugations, which often
reach several micrometers into the basal layer of the epidermis and are “hot spots”
for transdermal drug delivery because these pathways between the clusters of
corneocytes in the SC offer a lower transport resistance. However, comparing with
intercellular pathway, these intercluster pathways are sparse (12).
More specifically, the intercellular pathway width ranges from 0.4 to 36
nm, on average, with a peak around 20 nm, while the intercluster pathways are
much wider than 30 nm and almost permanently open (12). Moreover, the total
skin porosity is estimated to be no more than 0.25%, and a two-cell contact
equals to one-path approximation (12). In short, from the penetrant point of
view, the skin behaves as a mechanical, nanoporous barrier perforated by a
number of short, discontinuous, and gap-like penetration pathways (8).
Formulation Considerations for Transdermal Drug Delivery
Comparing other administration routes, the benefits offered by transdermal
drug delivery, as mentioned before, are attractive and impressive; however, it is
noteworthy that transdermal drug delivery is not able to achieve rapid and
immediate drug inputs, rather it is usually applied to hold a slow sustained
drug delivery or controlled drug input. Although there still remains a large pool
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of transdermal candidates that can benefit from this route of delivery, there are
only a handful of marketed transdermal agents that can be formulated to be
delivered across the skin passively. The key problem stems from the daily drug
dose that can be systemically delivered within a reasonable “patch-sized” area
less than 10 mg range due to the excellent diffusion resistance caused by the SC
(5). Consequently, this limitation imposes two criterions for a successful trans-
dermal candidate. The first one is that the pharmacological potency of transdermal
candidates must be high enough, usually requiring therapeutic blood concen-
trations in the ng/mL range or less, and the second one is that these candidates are
expected to possess acceptable physicochemical parameters related to molecular
hydrophobicity, molecular weight (size), and the ability to interact with the other
molecules, for example, via hydrogen bond formation (13–15).
Liposomal Vesicles as Transdermal Drug Delivery
It can be easily understood that not all drugs are suitable or feasible for trans-
dermal drug delivery. Hence, there exists a clear and pressing expectation by the
pharmaceutical scientists that the skin’s barrier could be technically breached to
enhance the transdermal flux across the skin and to expand the range of
transdermally delivered drugs. In fact, during the past decades, there has been
great interest in exploring new approaches to target this aim. These approaches
include the use of chemical penetration enhancers (16,17), chemical potential of
the drug (18), electrically driving molecules into or through the tissue employing
iontophoresis (19), or physically disrupting the skin structure by electroporation
or sonophoresis (20,21), and others (22,23). Colloidal drug delivery systems such
as liposomes, ethosomes, and transfersomes may offer a promising strategy for
approaching the purpose of improved skin drug delivery.
Essentially, liposomal vesicles are colloidal particles in which one or more
lipid bilayers entrap an aqueous volume. Their major components are usually
phospholipids, with or without some additives. There are a wide variety of
lipids and additives that can be used to prepare these vesicles. In light of their
changeable composition, liposomal systems can be classified into several types.
Most commonly, the vesicles only composed of phospholipids, with or without
cholesterol, can be called liposomes or conventional (traditional) liposomes. The
vesicles, which are structurally similar to liposomes but contain an additional
edge activator such as surfactants to modify the bilayer elasticity and to increase
deformability, are named ultraflexible liposomes, ultradeformable liposomes, or
transfersomes. Another kind of vesicle are ethosomes, which are also composed
of phospholipids but embodying a high concentration (20–45%) of alcohol
(ethanol or isopropyl alcohol). It is very possible that future research will lead to
the introduction and development of novel liposomal vesicles systems.
Moreover, it has to be pointed out that the diversity of potential composition
of these liposomal systems are influenced by their physicochemical characteristics
such as particle size, charge, thermodynamic phase, and bilayer elasticity, etc., which
in turn have a significant effect on the interaction between vesicles and the skin and
hence on the effectiveness of these vesicles as transdermal delivery systems.
Conventional Liposomes as Transdermal Delivery Systems
General and the effect of conventional liposomes on transdermal drug delivery. Several
studies have reported that conventional liposomes only enhanced the drug
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deposition in the skin, suggesting that they are only useful for dermal delivery
(24–28). However, others have suggested conventional liposomes being suitable
for transdermal delivery of some drugs (29–31). These inconsistent results can, at
least in part, be attributed to several possible discrepancies in different studies,
including different liposomal composition and physicochemical characteristics,
different vesicle preparation methods, different types of drugs loaded, different
assessment methods applied, different skin samples adopted, and different
application procedures administered. Although it is controversial whether
conventional liposomes are useful to enhance drugs for transdermal delivery,
but there is an agreement by specialists in this field that in most cases, con-
ventional liposomes are of little or no value as carriers for transdermal drug
delivery studies, because they do not penetrate the skin but remain confined to
upper layers of the SC (23) or form a deposit on the surface of the skin. Fur-
thermore, it was found that the thermodynamic state of the membranes (a liquid
state or a gel state) plays a vital role in its effectiveness as a skin delivery vehicle,
revealing that gel-state vesicles are less effective in increasing drug permeation
across the skin than liquid-state vesicles (32–35). Gel-state vesicles can even
inhibit drug permeation across the skin. However, other physicochemical
properties of the vesicles, such as size, lamellarity, and charge, have a less
pronounced effect on the drug permeation (36,37).
Mechanisms of action of conventional liposomes. The specific mechanism can fall into
one of three categories, including the intact vesicular skin penetration, the
penetration enhancing effect, and vesicle adsorption to and/or fusion with the
SC (38).
The use of vesicles for transdermal drug delivery has been introduced in
1980 (39). The statement that intact conventional liposomes can penetrate across
the skin was received with skepticism. Some studies supported that intact
vesicular penetration may be a possible mechanism for improved skin accu-
mulation (27,40), while others indicated that intact liposomes did not penetrate
the skin (36,41,42). Realistically, conventional liposomes such as colloids from an
aqueous suspension can cross the skin barrier only through hydrophilic path-
ways (intercellular route or intercorneocyte pathway). However, intact skin
contains only an insignificant number of pathways of sufficient width to allow
passage of even small colloids. Hence, any colloids that are trying to penetrate
through narrow pores of fixed size in the skin have to possess two capabilities: the
colloid-induced opening of the very narrow (~0.4 nm) gaps between cells in the
barrier to pores with a diameter greater than 30 nm, and self-adapting to the size of
20 to 30 nm without destruction (12). Obviously, conventional liposomes fall short
of these prerequisites. As a result, it is almost impossible for large conventional
liposomes to penetrate the densely packed SC in great numbers (38).
The penetration enhancing effect was the second possible mode of action
that was described in 1987 (43) and supported by others (42,44,45). They sug-
gested that liposome lipids may act as penetration enhancers, thereby loosening
the lipid structure of the SC and promoting an impaired barrier function (46).
However, negative findings have also been reported (47–49), claiming that the
penetration enhancing effect was invalid and liposomes must be applied con-
comitantly with the drug or the drug must be encapsulated within them (48).
The mechanism of vesicle adsorption to and/or fusion with the SC also
was reported by others (44,50,51), suggesting that liposome lipids penetrated
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into the SC by adhering onto the surface of the skin and subsequently desta-
bilizing and fusing or mixing with the lipid matrix (51). However, the collapse of
vesicles on skin surface may form an additional barrier, reducing the perme-
ation of hydrophilic molecules encapsulated in the vesicular aqueous core (52).
In summary, it can be concluded that conventional liposomes do not enter
the SC as intact entities, and the vesicle-skin interactions could occur either at
the skin surface or in the deeper layers of the SC, which will depend on the
compositions and the physicochemical properties of the liposomes.
Ultraflexible Liposomes as Transdermal Delivery Systems
General and the effect of ultraflexible liposomes on transdermal drug delivery. The ultra-
flexible liposomes, first introduced in 1992, are a novel type of liquid-state
modified liposomes named transfersomes1 and consist of phospholipids and an
edge activator (53,54). At the same time, a new physical parameter was intro-
duced, namely the elasticity of the vesicles bilayers (53). The presence of an edge
activator destabilizes the lipid bilayer of the lipid vesicles and increases the
deformability of the bilayer by lowering its interfacial tension. Hence, both the
type and concentration of the surfactants are most important in the formulation
of transfersomes. These edge activators employed include sodium cholate,
sodium deoxycholate, Span 60, Span 65, Span 80, Tween 20, Tween 60, Tween 80,
and others. Moreover, for the ultraflexible liposomes, the mode of application also
plays a crucial role in the vesicles-skin interactions. A few studies compared the
difference between occlusive and nonocclusive application of ultraflexible lip-
osomes, revealing that occlusive application of these vesicles was less effective
than the nonocclusive one (53,55). However, these results were a little bit of
unexpected because water has been reported to be an effective permeation
enhancer (56). According to the literature (53), the water gradient has been sug-
gested to be an important driving force for the ultraflexible liposomes. As a result,
driven by the osmotic gradient across the skin, these elastic vesicles nonocclusively
applied could follow the local hydration gradient and “squeeze” through the SC.
But contrarily, occlusion would dispel this osmotic gradient (53,57).
The effectiveness of ultraflexible liposomes as transdermal delivery sys-
tems has been successfully demonstrated by using numerous chemical agents of
different molecular sizes and lipophilicity, such as lidocaine, tetracaine, cyclo-
sporin, hydrocortisone, dexamethasone, triamcinolone acetonide, diclofenac,
ibuprofen, tamoxifen, testosterone, etc. (58). Furthermore, it has also been
reported that ultraflexible liposomes were able to deliver macromolecules and
proteins through the skin in preclinical experiments with a significant systemic
biological activity of these biomolecules, including calcitonin (58), insulin (59),
interferon (60,61), gap junction protein (62), and others (63–66). Hence, it was
even suggested that ultraflexible liposomes can be used as possible carriers for
noninvasive gene delivery and transcutaneous immunization.
Although most of these results indicated that ultraflexible liposomes can
improve transdermal drug delivery, some studies suggested that ultraflexible
liposomes were more useful for dermal than for transdermal delivery in the case
of ketotifen (67) and that the use of ultraflexible liposomes would even be
restricted for dermal delivery of a few drugs (68,69). Furthermore, it is notable
that ultraflexible liposomes are quite effective under in vivo conditions because
in vitro transport rates are much lower than in vivo (52,70).
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Mechanisms of action of ultraflexible liposomes. There are two possible mechanisms
responsible for the enhanced skin drug delivery via ultraflexible liposomes
(71,72). First, ultraflexible liposomes may act as drug carrier systems by which
intact vesicles enter the SC carrying vesicle-bound drug into or across the skin
(52). Direct supporting results have been published (57,73). Additional studies
have shown that pretreatment of skin membranes with empty deformable lip-
osomes did not enhance estradiol flux, while application of estradiol entrapped
within vesicles resulted in a 14- to17-fold increase in estradiol flux relative to
control (74). A reduction in vesicle size improved the deposition and penetration
of two fluorescently labeled model substances with large structures improving
the deposition only (75), and epidermal permeation enhancement via the
vesicular components in a lipid solution in 90% propylene glycol in water was
inferior (49), suggesting that ultraflexible liposomes may act as drug carriers and
are better for lipid components to be applied in the form of vesicles (49).
However, in case of accepting this mechanism, as mentioned before, two pre-
requisites are necessary: the sufficient carrier stability on the skin and hydro-
philic pore opening in the skin by such vesicles (12). This is why only well-
designed ultraflexible liposomes can overcome the skin barrier posed by the SC.
On the other hand, the water gradient was regarded as the driving force for
ultraflexible liposomes entering the skin (53). However, the water gradient
across the skin may not be linear, consequently, as a result of the osmotic force
such vesicles will not penetrate beyond the level of the lowest layers in the SC
(76). Hence, the drugs will be released first from such vesicles and then pene-
trate alone to reach the systemic circulation (72).
Second, vesicles may act as penetration enhancers, whereby membrane
bilayers as vesicles interact with the SC and subsequently modify the inter-
cellular lipid lamellae. It has been shown that deformable liposomes were able
to carry both the entrapped and the nonentrapped carboxyfluorescein (albeit to
a lesser extent) into the SC and possibly to deeper layers (77), enoxacin per-
meation across lecithine-treated skin was higher than that across nontreated skin
after 12 hours of pretreatment (78), indicating that this mechanism is also rea-
sonable.
Hence, most possibly, both mechanisms play a role in the enhanced
transdermal delivery of drugs by ultraflexible liposomes under nonocclusive
conditions. It is possible that one of the two mechanisms might predominate
according to the physicochemical properties of the drug considered (52).
Ethosomes as Transdermal Delivery Systems
General and the effect of ethosomes on transdermal drug delivery. Ethosomes are another
novel permeation-enhancing lipid vesicles (79) that are composed of phospho-
lipid and a high concentration (20–45%) of ethanol and water. The effect of
ethanol and its concentration on the physicochemical characteristics of the
ethosomes have been investigated (67,79,80). As reported, ethanol can confer a
surface negative net charge to the liposome, which in turn causes the size of
vesicles to decrease (79,81). The decrease of ethanol concentration in the range of
20% to 45% can result in the increase in the size of ethosomes (79). Moreover,
due to the multilamellarity of ethosomes (79), the presence of ethanol in etho-
somes, and the solubility of many drugs, ethosomes can exhibit high encapsu-
lation efficiency and drug loading.
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Because of their unique structure, ethosomes can entrap and effectively
deliver highly lipophilic molecules and cationic drugs such as acyclovir, tri-
hexyphenidyl, minoxidil, cannabinoids, zidovudine, and testosterone through
the skin (22,79,82). More interestingly, unlike ultraflexible liposomes, ethosomes
are able to improve the skin delivery of drugs both under occlusive and non-
occlusive conditions (67,79,81,83), depicting a different mechanism of action for
ethosomes.
Mechanisms of action of ethosomes. Although the exact process of skin drug delivery
by ethosomes remains unclear, it appears that a synergistic mechanism between
ethanol, lipid vesicles, and skin lipids facilitates drug delivery to the deeper skin
layers or across the skin (79,80,84).
At first, ethanol must be responsible for the enhanced skin drug delivery
described. Ethanol is a well-known permeation enhancer. It can interact with
intercellular lipid molecules in the polar head group region, thereby increasing
their fluidity and decreasing the density of the lipid multilayer, which results in
an increase in membrane permeability. Ethanol is also supposed to extract the
SC lipids and these penetration enhancement effects may be referred to as “pull-
effects” (85). In addition, ethanol imparts flexibility to the ethosomal vesicles,
which in turn facilitates skin permeation. Furthermore, ethanol can act as a
“blending” agent (86) for lipid vesicles, increasing their distribution in various
skin layers.
The ethanol effects are followed by the interaction between ethosome
vesicles and the skin. The interdigitated, malleable, ethosome vesicles behave as
ultraflexible liposomes and can interact with the skin barrier to “forge” pene-
tration or permeation pathways by itself in the highly organized SC and finally
release drug at various points along the penetration pathway as well as in deep
skin layers (52,82).
Liposomes for the Protection of Damaged Skin
The barrier function of damaged skin is diminished in comparison to healthy
skin. Therapeutic agents may have an easier access to damaged skin. Damaged
skin could use liposomes consisting of skin lipids to fill the damaged skin area.
Higher drug concentrations can be established in this damaged skin by
liposomes, either by penetrating deeper into the damaged skin or by depositing
drug on the top of the damaged area, thereby protecting the damaged area by
spreading the liposomal lipids on top. These synergizing effects may explain the
beneficial effects of liposomes in reducing the toxicity of herbal and drug
compounds encapsulated in liposomes (87).
One of the first drugs in a commercialized liposomal formulation for
topical administration was an econazole liposome gel. A comparative study
revealed that, in contrast to the commercial cream formulation, the liposome gel
formulation had less toxic effects and no candidosis was detected in a recon-
structed human epidermis model of human cutaneous candidosis (88).
Substances that can be degraded on the way to the target cells in the
damaged skin can be protected by encapsulating them in liposomes, which is
important for proteins and nucleic acids. A recent study on xeroderma pig-
mentosum, where a DNA repair enzyme mechanism (endonuclease) was
applied in a liposomal formulation, demonstrated protection (89,90). Also, the
Liposomes as Tools for the Skin Delivery and Protection 295
To
xi
co
lo
gy
 o
f t
he
 S
ki
n 
D
ow
nl
oa
de
d 
fr
om
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
Y
al
e 
U
ni
ve
rs
ity
 o
n 
11
/1
7/
10
Fo
r p
er
so
na
l u
se
 o
nl
y.
effect of superoxide dismutase as racidal-capturing agent was enhanced when
encapsulated in liposomes and spread onto the wounds in an animal model (91).
IL-13 antisense oligonucleotides were formulated with cationic flexible lip-
osomes, and in a murine model a significant improvement was seen in atopic
dermatitis skin (92). By the additional use of DMSO as a penetration enhancer,
liposomes served as vectors in gene therapy through intact chicken skin (93).
In addition, the general protection of the skin by antioxidants, such as a-
tocopherol, has enhanced using liposomes in an in vitro model (94).
Doxorubicin liposomal formulations administered intravenously did not
cause as much skin lesions as the free form of doxorubicin because the liposomal
administered doxorubicin did not extravasate—and did not go into the skin—as
strongly as the free doxorubicin (95). The same findings were reported for vin-
cristine (96). In both formulations less skin irritation was seen at the site of injection.
In summary, whatever mechanism may be involved in the interaction or
penetration of liposomes into the skin, beneficial effects were seen in some
compounds. It is recommended that for each new drug intended for topical
application, the liposomal formulations should be screened for better efficacy
and/or a reduced toxicity.
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The aim of the present research is to evaluate the skin delivery capabilities of different vesicu-
lar systems, including conventional liposomes (CL), Tween 80-based deformable liposomes (DL),
invasomes (INS) and ethosomes bearing ferulic acid (FA) being an antioxidant exhibiting a wide
range of therapeutic effects against various diseases. All of the test formulations were characterized
for particle size distribution,-potential, vesicular shape and surface morphology, in vitro human
skin permeation and skin deposition. Dynamic Light Scattering (DLS) and Transmission Electron
Microscopy (TEM) deﬁned that all of liposomal vesicles were almost spherical, displaying unilamel-
lar structures with low polydispersity (PDI < 02) and nanometric size range (z-average no more
than 150 nm). In addition, all the vesicular systems except conventional liposomes were negatively
charged to a certain extent. In vitro skin permeation and skin deposition experiments demonstrated
that the permeation proﬁle of ferulic acid through human stratum corneum epidermis membrane
(SCE) and the drug deposition in skin were both improved signiﬁcantly using these vesicular lipo-
somal systems. Permeation and skin deposition enhancing effect was highlighted by the ethosomal
system containing 18.0 mg/ml of ferulic acid with an signiﬁcantly (P < 001) enhanced skin ﬂux
(2678±1677 g/cm2/h) and skin drug deposition (5167±194 g/cm2, which was 75 times and
7.3 times higher than those of ferulic acid from saturated PBS (pH 7.4) solution, respectively. This
study demonstrated that ethosomes are promising vesicular carriers for delivering ferulic acid into
or across the skin.
Keywords: Ferulic Acid, Skin Delivery, Liposomes, Invasomes, Ethosomes, In Vitro Skin
Permeation, Skin Deposition.
1. INTRODUCTION
There is always a lurking but reasonable expectation from
both public and scientiﬁc community that many human
diseases could be treated by phytochemicals derived
from dietary components. Ferulic acid (3-(4-hydroxy-3-
methoxyphenl)-2-Propenoic acid, C10H10O4, FA) (Fig. 1),
is present in the cell walls of numerous plants, includ-
ing rice, wheat, barley, oat, vegetables, citrus fruits and
leaves, and many other plants.1 Nowadays, Ferulic acid
is receiving greater attention in science because it has
an established record of therapeutic effects against var-
ious diseases such as anti-skin disorders, anti-cancer,
anti-ageing, anti-diabetes, anti-cardiovascular disease, neu-
roprotection, anti-inﬂammatory and others.2 This arises
mainly from its antioxidant property by virtue of its
phenolic nucleus and unsaturated side chain forming a
∗Author to whom correspondence should be addressed.
resonance-stabilized phenoxy radical (Fig. 2). The thera-
peutic concentration varies with the diseases under consid-
eration; for anti-oxidant effective concentration.
Ferulic acid (FA) is the main effective constituent in a
few of traditional Chinese medicinal herbs, such as Dang
gui (Radix Angelica sinensis), Chuan xiong (Ligusticum
chuanxiong Hort.) and A wei (Ferula sinkiangensis K. M.
Shen). These Traditional Chinese herbs have been widely
used for the prevention and treatment of many diseases
since antiquity in China, such as headaches, abdominal
ache, chest pain, muscle pain, boils, difﬁculty in menses,
amenorrhea and rids of blood stasis.3 In recent years FA
has been already formulated into injection, infusion and
tablets in Chinese market to treat cardiovascular diseases.
But, due to its short elimination half-life (t1/2 < 15 min)
after intravenous or intragastric administration, it needs to
be administered quite frequently resulting in reduction of
patients’ compliance.3 Hence, transdermal delivery of FA
is expected to be a better alternative to traditional admin-
istration routes. This assumption is supported by the fact,
that because of its imparting cutaneous beneﬁts,4 FA is
J. Biomed. Nanotechnol. 2010, Vol. 6, No. 5 1550-7033/2010/6/001/009 doi:10.1166/jbn.2010.1154 1
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CH3O
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Fig. 1. Structure of ferulic acid.
also found as an active ingredient in a variety of cos-
metics products such as facial moisturizer/treatment, anti-
aging, skin fading/lightener, facial cleanser. Together with
its satisfying physico-chemical properties for skin deliv-
ery (small molecular weight: 194.2 Dalton; its amphiphilic
nature as having a carboxyl group attached via a short
hydrocarbon group to a lipophilic phenolic nucleus; a
logPoct of 1.51 and a solubility of FA in PBS (pH 7.4)
736± 023 mg/mL), it was tempting for us to try to
develop a delivery system for FA.
Despite many attempts to deliver drugs via topical
administration, only a few cases were successful. The
key problem is the formidable barrier function by the
stratum corneum (SC), the outermost layer of the skin.
During the past decades there has been wide inter-
est in exploring new approaches to overcome this sit-
uation. These approaches include the use of chemical
penetration enhancers,56 adjustment of chemical poten-
tial of the drug,7 driving molecules into or through
the tissue employing iontophoresis8 or physically dis-
rupting the skin structure, for example by electropora-
tion or sonophoresis910 and other means.1112 Vesicular
drug delivery systems such as conventional liposomes,13
ethosomes14 and transfersomes1516 also offer a promis-
ing strategy for achieving the purpose of improved skin
drug delivery. It should be pointed out that the great diver-
sity of potential composition of these vesicles inﬂuences
their physicochemical characteristics such as particle size,
charge, thermodynamic phase and bilayer elasticity, which
in turn have a signiﬁcant effect on the interaction between
vesicles and the skin and hence on the effectiveness of
these vesicles as transdermal delivery systems.
The present work focuses on developing a suitable
vesicular system for the skin delivery of ferulic acid and
investigating the inﬂuence of different vesicular systems
on the percutaneous absorption of FA.
O O O O O
COOH COOH COOH COOH COOH
OCH3 OCH3 OCH3 OCH3 OCH3
Fig. 2. Resonance stabilization of FA radical.
2. MATERIALS AND METHODS
2.1. Chemicals and Instruments
Lipoid S 100 (Phosphatidylcholine from soybean lecithin)
was purchased from Lipoid GmbH, Germany. NAT 8539
(Soybean phosphatidylcholine (PC) dissolved in ethanol
containing: 77.3% phosphatidylcholine, 5% lysophos-
phatidylcholine, 3% cephaline and 1.1% phosphatidic
acid of the dry residue) was purchased from Natter-
mann Phospholipid GmbH, (Hermersberg, Germany). Fer-
ulic acid was purchased from Sigma-Aldrich, (Steinheim
am Albuch, Germany). DPPG (1, 2-dipalmitoylsn-glycero-
3- phosphatidylglycerol) was purchased from Genzyme
Pharmaceuticals, Sygena Facility, (Liestal, Switzerland).
Limonene, Citral and Cineole were purchased from Sigma-
Aldrich, (Steinheim am Albuch, Germany). All other sol-
vents used in this study were of analytical grade and were
purchased from Merck, (Darmstadt, Germany).
2.2. Preparation of Vesicular Formulations
All vesicular systems were prepared by a conventional
rotary evaporation method.1718 Brieﬂy, the appropriate
weight of lipid or lipids and FA (the compositions of
different vesicular systems are shown in Table I) were
dissolved in methanol/chloroform solution (1:2, v/v) in
round bottom ﬂask. Thin lipid ﬁlms were obtained by
removing the organic solvents under vacuum condition
(500 mbar 10 min, 200 mbar 10 min, 100 mbar 10 min,
35 mbar 1 hr) at a temperature of 43 C with a
rotary evaporator. The resulted dry lipid ﬁlms on the
inside wall of round bottom ﬂask were hydrated and
dispersed with different hydration systems correspond-
ing to all formulations (Table I) at room temperature.
The obtained macroscopically homogenous solution was
sonicated for totally 15 minutes in 3 cycles (5 min for
each cycle and 5 min pause among these cycles) with
a sonication ice-water bath. The obtained suspensions
were extruded through polycarbonate membrane (diame-
ter: 19 mm, pore diameter: 100 nm, Armatis, Germany)
21 times to produce liposomes of the desired size with the
help of a Hamilton-Bonaduz extruder (GASTIGHT#1001,
Switzerland).
2 J. Biomed. Nanotechnol. 6, 1–9, 2010
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Table I. Composition of different vesicular systems and control groups.
Code Lipids and other components (mg/ml) Ferulic acid (mg/ml) Solvent system
CLa Lipoid-s100, 40.0 12.0 PBS (pH 7.4)
Cholesterol, 3.0
DLb Lipoid-s100, 40.0 12.0 PBS (pH 7.4)
Tween 80, 8.5 Ethanol (10%, v/v)
INSc NAT8539, 133.0 12.0 PBS (pH 7.4)
Terpenesd , 10.0 Ethanol (10%, v/v)
ETS-1e Lipoid-s 100, 40.0 12.0 Water
DPPG, 2.0 Ethanol (45%, v/v)
ETS-2e Lipoid-s 100, 40.0 18.0 Water
DPPG, 2.0 Ethanol (45%, v/v)
CTL-1f — 12.0 Water
Ethanol (45%, v/v)
CTL-2f Lipoid-s 100, 40.0 12.0 Ethanol
CTL-3f — 7.4 g PBS (pH 7.4)
aConventional liposomes; bTween 80-based deformable liposomes; cInvasomes; dTerpenes mixture (Limonene:citral:cineole= 1:4.5:4.5, v/v); eEthosomes; fControl group;
gSaturated solution.
2.3. Characterization of Vesicular Systems
2.3.1. Particle Size Distribution and -Potential
Measurement
The particle size, polydispersity index (PDI) and
-potential of the vesicular systems were determined by
photon correlation spectroscopy (Zetasizer Nano series,
Malvern Instruments Ltd., Worcestershire,UK). Before the
size and -potential measurements, the samples were
diluted 50-times with different solvent systems corre-
sponding to their compositions (Table I), which were
also ﬁltered through polycarbonate membrane (Minisart®
syringe end ﬁlters 0.2 m, Sartorius AG, Goettingen, Ger-
many). Measurements were made at 25 C with a ﬁxed
angle of 137. Sizes quoted are the z-average mean for the
hydrodynamic diameter.11 Calculation of -potential (mV)
was done by the instrument software from the measured
electrophoretic mobility.19
2.3.2. Visualization by Cryo-Transmission Electron
Microscopy
The different vesicular systems (CL, DL, INS and ETS-
2) were visualized by cryo-electron microscopy, which
allowed beside shape investigation also the measurement
of the lipid lamellarity. 5 L of test formulation were
placed on a perforated copper grid (Quantifoil R 1.2/1.3)
and excess liquid was blotted automatically for two sec-
onds between two pieces of ﬁlter-paper-strips. Shortly after
that, the samples were frozen by rapidly plunging in liq-
uid ethane (cooled to 170∼180 C) in a cryo box (Carl
Zeiss NTS GmbH, Germany). Excess ethane was removed
with a piece of ﬁlter paper in the cryo box. The sam-
ple was transferred with the liquid nitrogen cooled holder
(Gatan 626, USA) into the pre-cooled cryo-electron micro-
scope (Phillips CM 120, Netherlands) operated at 120 kV
and viewed under low dose conditions. The Images were
recorded with a 1 k CCD Camera (FastScan F114, TVIPS,
Gauting, Germany).
2.4. Skin Preparation
Female human abdominal skin tissue from plastic surgery
was used. The stratum corneum/epidermis (SCE) mem-
branes were prepared by a heat separation technique.20–22
After removal of excess fat and connective tissue, the skin
was soaked for 2 min in a water bath at 60 C. Then the
epidermis was carefully peeled away from the dermis. The
SCE membranes were dried in desiccators at ∼25% rela-
tive humidity23 and frozen at −20 C for later use up to
3 months after storing. Before use, the epidermis mem-
branes were ﬂoated with the stratum corneum side up on
receptor medium and the upper surface was left open to
the atmosphere overnight at 4 C. After verifying of the
integrity by transepidermal water loss (TEWL) measure-
ments (VapoMeter, Delﬁn Technology Ltd., Kuopio, Fin-
land) it was also ensured, that samples were free from any
surface irregularity such as tiny holes or crevices in the
portion that was used for the permeation studies.
2.5. In Vitro Skin Permeation and Deposition Studies
In Vitro skin permeation and deposition experiments of
the vesicular systems containing FA were run in Franz
diffusion cells with the formulations applied in a non-
occlusive way; the skin surface temperature was kept at
32 C throughout the experiment. The effective permeation
area and receptor cell volume was 0.64 cm2 and 5.4 ml,
respectively.
The design in the present study was the same as
described by El Maghraby et al.24 Experiments were per-
formed in two stages. The ﬁrst stage was for determina-
tion of the drug permeating across the skin. In this stage,
PBS buffer pH 6.0 was used as the receptor medium. Skin
membranes were mounted, with the stratum corneum side
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up and the donor compartment dry and open to atmosphere
for 0.5 hr. 100 l of the test formulations were applied
to skin surface. 0.5 ml of the samples were removed
from receptor cells at appropriate intervals (at 0, 1, 2, 3,
4, 5, 6 and 8 hr) for the concentration measurement by
ﬂuorescence assay using a Fluostar (Optima Microplate
Reader, BMG LABTECH GmbH. Offenburg, Germany)
and immediately replaced with fresh medium. At the end
of this stage (8 h), the donor compartment and the skin
surface were washed ﬁve times with warm (45 C) recep-
tor medium.
The second stage was employed to determine the
deposited drug in skin. The skin samples were transferred
into special tubes loaded with 0.55 gm of ceramic pel-
lets. For the extraction of FA 1 ml of ethanolic solu-
tion (50%, v/v) was added to each tube. The skin was
homogenized by a Precellys S24 device (Berlin Tech-
nology, Bad Wildbad, Germany) with the following set-
tings: 6000 rpm, 3 cycles each 30 s. The dispersions
were ultra-centrifugated (10 min, 10000 rpm, Minispin®,
Eppendorf, Germany) to remove remaining skin debris.
The supernatant was collected, diluted with ethanol solu-
tion (50%, v/v) and analyzed by ﬂuorescence measure-
ment. Each vesicular system was investigated in triplicate.
FA ﬂux through the skin was calculated by plotting
the cumulative amount of drug permeating across the skin
against time and determining the slope of the linear por-
tion of the curve and the x-axis-intercept values (lag time)
by linear regression analysis. Drug ﬂux (g/(cm2 ∗h)), at
steady-state, was calculated by dividing the slope of the
linear portion of the curve by the area of the skin surface
covered with formulation. Statistical analysis of data was
performed using Student’s t-test.
The effectiveness of different vesicular systems to
deliver FA across or into the skin was determined by com-
paring FA ﬂux and skin deposition between the different
test formulations and PBS (pH 7.4) saturated solutions of
FA as standard, these ratios were deﬁned as the enhance-
ment ratio of ﬂux (ERﬂux or as the enhancement ratio of
skin deposition (ERdeposition:
ERﬂux
= ferulic acid ﬂux at steady−state from test formulationferulic acid ﬂux at steady−state from PBS PH74 saturated solution (1)
ERdeposition
= ferulic acid skin deposition from test formulationferulic acid skin deposition from PBS PH74 saturated solution (2)
2.6. Fluorescent Assay of FA
The concentration of FA was determined by ﬂuorescence
spectroscopy method. Fluorescence detection was per-
formed at an excitation wavelength of 355 nm and an emis-
sion wavelength of 460 nm. The method was validated for
linearity, accuracy and precision.
2.7. Data Analysis
All reported data are mean± S.E.M. Statistical signiﬁ-
cance was checked by Student’s t-test and considered to
be signiﬁcant at P < 005, unless indicated using Minitab®
Ver.14 software.
3. RESULTS
3.1. Particle Size Distribution and -Potential
The results of particle size distribution and -potential
of the investigated vesicular systems are summarized in
Table II. Regarding vesicle size, the largest vesicles of
1303± 47 nm (n = 3 were present in conventional
liposome formulations, while Tween 80-based deformable
liposomes (934± 16 nm), ethosomes (889± 07 and
921± 30 nm (n = 3)) in the case of ethosomes con-
taining 12.0 mg/ml and 18.0 mg/ml of FA, respectively)
had signiﬁcantly P < 001) lower mean vesicle sizes
relative to conventional liposomes. All vesicular systems
exhibited low polydispersity index (PDI) values (PDI <
02), indicating that all of them were highly homogeneous
suspensions.
The -potential is related to the charge on the surface of
the vesicle inﬂuencing vesicular properties such as stability
and skin–vesicle interactions. Conventional liposomes as
prepared in this study were found to possess a -Potential
of 29±04 mV (n= 3). Tween 80-based deformable lipo-
somes exhibited a -Potential of −63± 01 mV (n = 3).
Invasomes also exhibited a negative -Potential of −397±
20 mV (n = 3). This result is in reasonable agreement
with other data on invasomes from our group.2526 Etho-
somes containing 12 and 18 mg/ml of FA showed similar
-Potentials of −373±16 and −302±09 mV (n= 3),
respectively. In this case, incorporation of ethanol, as well
as DPPG, a negatively-charged phospholipid,27 is expected
to produce negatively charged vesicles.
3.2. Morphology of Different Liposomal Vesicles
Cryo-transmission electron microscopy was used to visu-
alize vesicles, and to study the shape and lamellarity of
Table II. Characterization of different vesicular systems containing fer-
ulic acid.
Code Particle size PDIf −potential (mV)
CLa 1303±47 0110±0008 29±04
DLb 934±16g 0044±0013 −63±01
INSc 1291±13 0112±0007 −397±20g
ETS-1d 889±07g 0082±0025 −373±16g
ETS-2e 921±30g 0088±0022 −302±09g
Values represent mean ±SD (n = 3). aConventional liposomes; bTween 80-
based deformable liposomes; cInvasomes; dEthosomes containing ferulic acid
(12.0 mg/ml); eEthosomes containing ferulic acid (18.0 mg/ml). f Polydispersity
index; gp < 001 in comparison with Conventional liposomes (CL);
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all vesicular systems, including CL, DL, INS, and ETS-2.
From the results (Fig. 3), the vesicles of the conventional
liposomes seemed to be mostly unilamellar (Figs. 3(a
and b), black light arrows) with rare occasions of bil-
amellarity (Figs. 3(a and b), black thick arrows). In the
case of Tween 80-based deformable liposomes, the vesi-
cles were also mostly unilamellar (Figs. 3(c and d), black
light arrows) and bilamellar (Figs. 3(c and d), black thick
arrows) and a small percentage of oligolamellar vesicles
(Fig. 3(c), black long length arrow). Regarding Invasomes,
the vesicles seemed to be also unilamellar (Fig. 3(f), black
short length arrow) and some bilamellar (Fig. 3(f), black
thick arrows), but the percentage of deformed vesicles
increased dramatically in comparison to other liposomal
structures (Figs. 3(e and f), white light arrows). In com-
parison to other vesicles, ethosomal vesicles appeared to
be homogenously unilamellar (Figs. 3(g and h), black light
arrows).
3.3. In Vitro Skin Permeation and Skin Deposition
Studies
The abilities of different liposomal systems and related
control groups to deliver FA were investigated by deter-
mining the ﬂux of FA across SCE (Jss, lag time (LT)
and the quantity of skin deposition of the drug (QSD).
The results are summarized in Table III. The cumulative
Conventional liposomes Invasomes Ethosomes-2Tween 80-based
deformable liposomes
Fig. 3. Visualization of different liposomal systems containing ferulic acid by cryo-transmission electron microscopy. (a, b) conventional liposomes
containing 12 mg/ml of ferulic acid; (c, d) Tween 80-based deformable liposomes containing 12 mg/ml of ferulic acid; (e, f) invasomes containing
12.0 mg/ml of ferulic acid; (g, h) ethosomes containing 18.0 ng/ml of ferulic acid. Black light arrows represent unilamellar vesicles; black thick arrows
represent bilamellar vesicles, while white thick arrows represent oligolamellar vesicles, white small arrows represent deformed vesicles.
amount of FA permeated per unit area across SCE via vari-
ous formulations was plotted as a function of time (Fig. 4).
From the results, all the elastic vesicular systems includ-
ing Tween 80-based deformable liposomes (DL), Inva-
somes (INS) and ethosomes (ETS-1 and ETS-2) showed a
better permeation proﬁle than the PBS saturated solution
group (CLT-3). Furthermore, it could be clearly demon-
strated that the amount of FA permeated through the human
SCE skin in vitro from ethosomes containing 18 mg/ml of
FA (ETS-2) was signiﬁcantly (P < 001) higher than that
from all other formulations. The ﬂux from ethosomes con-
taining 18 mg/ml of FA (ETS-2, 2678±1677 g/cm2/h)
was 7-fold higher than that obtained after application of
4% phospholipid in ethanol solution (CTL-2, 3320 ±
917 g/cm2/h), 11-fold higher than that of the ethanol
solution of drug (CTL-1, 2062± 128 g/cm2/h), 75-fold
higher than that of the drug saturated solution in PBS (pH
7.4) (CTL-3, 358±269 g/cm2/h), 9-fold higher than that
of conventional liposomes (CL, 2934± 978 g/cm2/h),
5-fold higher than that of Tween 80-based deformable lipo-
somes and invasomes (DL.5200± 1290 g/cm2/h and
INS, 5457±1386 g/cm2/h) and 2.5-fold higher than that
of ethosomes containing 12 mg/ml of FA (ETS-1, 1150±
1121 g/cm2/h). All the proﬁles were suitable to be ﬁt-
ted by a zero-order equation, and all showed the typi-
cal time lag of skin delivery, which represents the time
required to establish steady state diffusion and corresponds
J. Biomed. Nanotechnol. 6, 1–9, 2010 5
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Table III. Permeation and skin deposition parameters of ferulic acid via different formulations.
Formulation code Jssg (g/cm2/h) LTh (hours) Pmi (cm/h×10−3 ER jp QSDk (g/cm2 ERld
CLa 2934±978 2.8 0.3 8.2 3461±067 4.9
DLb 5200±1290 1.2n 0.5 14.5 1577±040 2.2
INSc 5457±1386 1.8n 0.6 15.2 2131±046 3.0
ETS-1d 1150±1121 0.9n 1.2 32.1 2323±104 3.3
ETS-2e 2678±1677m 1.7n 1.9 74.7 5167±194m 7.3
CTL-1f 2062±128 2.2o 0.2 5.8 598±017 0.8
CTL-2f 3320±917 2.7 0.3 9.3 1784±034 2.5
CTL-3f 358±269 2.9 0.1 — 708±027 —
Values represent mean ± SD (n = 3). aConventional liposomes; bTween 80-based deformable liposomes; cInvasomes; dEthosomes containing ferulic acid (12.0 mg/ml);
eethosomes containing ferulic acid (18.0 mg/ml); f p < 001 in comparison with all other formulations, gSteady state transdermal ﬂux; hLag time; iPermeability coefﬁcient;
jEnhancement ratio of skin ﬂux from formulation to PBS saturated drug solution; kQuantity of skin deposition; lEnhancement ratio of amount of drug deposition from
formulation to PBS saturated drug solution; mcontrol group; np < 001 in comparison with control group 3, op < 005 in comparison with control group 3.
to the nonlinear portion of a permeation proﬁle. Among all
formulations, the elastic liposomes showed a signiﬁcantly
smaller (P < 001) time lag, ranging from 0.9 hr to 1.8 hr,
as compared with the lag time (2.9 hr) of PBS saturated
solution (CTL-3), indicating that elastic liposomes could
reduce the needed time for delivery systems to reach the
steady state. Moreover, the ethanol solution of drug (CTL-
1) also showed relatively smaller (P < 005 time lag, sug-
gesting that the presence of ethanol in delivery system
reduces the equilibration time in the skin layer investigated.
Regarding skin deposition studies, both conventional
liposomes (CL) and elastic liposomal systems (DL, INS,
ETS-1 and ETS-2) led to better drug deposition in the skin
(epidermis) layer. The enhanced skin depositions of differ-
ent formulations were clearly illustrated in Table III and
Figure 5. As shown, the ethosomes containing 18 mg/ml
of FA (ETS-2) also induced the highest skin deposition
(5167± 194 g/cm2 of FA. In contrast, the skin depo-
sition of ferulic acid from PBS saturated solution group
(CLT-3) was only 708±027 g/cm2. Among other inves-
tigated formulations, the conventional liposomes showed
the second highest skin deposition, 3461±067 g/cm2.
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Fig. 4. Permeation proﬁles of ferulic acid through human SCE skin
from different formulations after 8 hrs. Note, CL: Conventional lipo-
somes; DL: Tween 80-based deformable liposomes; INS: Invasomes;
ETS-1: ethosomes containing ferulic acid (12.0 mg/ml); ETS-2: etho-
somes containing ferulic acid (18.0 mg/ml); CTL-1: ethanol solution con-
taining ferulic aid (12.0 mg/ml); CTL-2: 4% (m/v) phospholipid ethanol
solution containing ferulic aid (12.0 mg/ml); CTL-3: PBS (pH 7.4) satu-
rated solution of ferulic acid; values represent mean±SD (n= 3).
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Fig. 5. Cumulative permeated and skin deposition of ferulic acid via
human SCE skin from different formulations after 8 hr. Note, CL:
Conventional liposomes; DL: Tween 80-based deformable liposomes;
INS=Invasomes; ETS-1: ethosomes containing ferulic acid (12.0 mg/ml);
ETS-2: ethosomes containing ferulic acid (18.0 mg/ml); CTL-1: ethanol
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lipid ethanol solution containing ferulic aid (12.0 mg/ml); CTL-3: PBS
(pH 7.4) saturated solution of ferulic acid; QSD: Quantity of skin deposi-
tion of ferulic acid; CPA: Cumulative permeated amount of ferulic acid.
Values represent mean±SD (n= 3).
4. DISCUSSION
4.1. Particle Size Distribution and -Potential
One of the reasonable explanations about the reduced size
of elastic liposomal systems is the presence of ethanol
in these formulations. Ethanol could probably reduce the
membrane thickness due to the formation of a phase with
interpenetrating hydrocarbon chains.2829 Furthermore, the
addition of ethanol in phospholipid vesicles imparts nega-
tive charge to the formulation,14 which also explains there
a net change ﬂip over from conventional liposomes to
other vesicles with ﬂuid bilayers with the presence of
ethanol. This modiﬁcation of net charge of liposomal sys-
tems confers lipid vesicles some degree of steric stabiliza-
tion and in turn lead to decrease in mean vesicle size.30
All of these mechanisms suggested that the ethanol pos-
sess some condensing ability for lipid vesicles. Moreover,
in case of Tween 80-based deformable liposomes, reduc-
tion of particle size could also be explained by inclusion
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of the surfactant.31 While in case of invasomes, lysophos-
phatidylcholine (LPC), as one of the components of the
NAT 8539, has a single hydrophobic chain and a polar
head group and integrates spontaneously into membrane
bilayers, is acting as a surfactant and creating a high pos-
itive curvature in membranes.32 However, the inclusion of
1% (w/v) terpene mixture could lead to the increase of
particle size distribution 1291± 13 nm (n = 3).26 The
effect of surface charge of liposomes on the drug penetra-
tion has not been fully understood so far. Some researchers
support the theory that the positive charges on the sur-
face of liposomes could bind to negative charges of the
SC enhancing the drug penetration/permeation through the
skin.3334 However, other studies found that permeation of
drugs through the skin is promoted by negatively charged
vesicles.3536 In our previous study (data not shown here),
the ﬂux of FA from negatively charged ethosomes is some-
what higher than from positively charged ethosomes, but
without any signiﬁcant difference. In case of amphiphilic
drug such as FA, we suggested that the surface charge of
the vesicles will not only play a role on the interaction
between skin and vesicles but also might contribute to the
drug release from the vesicles. The drug release from vesi-
cles in the stratum corneum is an important step which will
affect transdermal ﬂux.37 The rate and amount of released
drug is a balance between two factors: (1) drug afﬁnity to
vesicles, and (2) drug solubility in lipids of the stratum
corneum.37 Since the pKa1 of Ferulic acid
38 is 4.52, it is
negatively ionized at pH = 7.4 and therefore it could be
retained in the positively charged vesicles, which in turn
inﬂuences the skin penetration or permeation.
4.2. Morphology of Vesicular Systems
Since all of the vesicular systems were prepared with an
extrusion procedure as described, the vesicles from differ-
ent liposomal systems are supposed to be mostly unilamel-
lar, which already have been conﬁrmed from the results in
this study. Furthermore, the increase of deformed vesicles
in invasomes suspensions can be explained as the incor-
poration of 1% of terpenes into the vesicles, which had
an inﬂuence on the ultraﬂexibility of these vesicles. This
ﬁnding is in accordance with the results published in other
research of our department.2526
4.3. In Vitro Skin Permeation and Skin Deposition
Studies
Due to the barrier function of the skin, the development
of an appropriate drug skin delivery system is particularly
important to overcome this situation. In spite of extensive
studies conducted concerning the effect of various lipo-
somal systems on percutaneous absorption, their mecha-
nism of action still remains unclear. However, it has to
be pointed out that the diversity of potential composition
of these liposomal systems could inﬂuence their physico-
chemical characteristics such as particle size, charge, ther-
modynamic phase, bilayer elasticity, etc., which in turn
have a signiﬁcant effect on the interaction between the par-
ticles and the skin and hence on the effectiveness of these
structures as transdermal delivery systems.
Conventional liposomes were expected to be effective
at delivering drugs into the upper layers of the skin. It is
agreed in the recent literature, that in most cases conven-
tional liposomes are of little or no value as carriers for
transdermal drug delivery, as they are not penetrating the
skin but remain conﬁned to upper layers of the SC39 or
form a deposit on the surface of the skin. The result in
this study supports this notion. The penetration properties
of conventional liposomes may fall into one of two possi-
ble categories, including the penetration enhancing effect
and vesicle adsorption to and/or fusion with the SC.40 The
ﬁrst possible mode of action that was described ﬁrstly in
198741 and supported by others.42–44 This mode suggests
that liposome lipids may act as penetration enhancers,
thereby loosening the lipid structure of the SC and pro-
moting an impaired barrier function.44 The second possible
mode for conventional liposomes is adsorption to and/or
fusion with the SC,434546 suggesting that the liposomal
lipids penetrate into the SC by adhering onto the surface
of the skin and subsequently destabilizing and fusing or
mixing with the lipid matrix.46 However, the collapse of
vesicles on skin surface may form an additional barrier,
reducing the permeation of hydrophilic molecules encap-
sulated in the vesicular aqueous core.47
Tween 80-based deformable liposomes and Invasomes
showed better permeation proﬁles and enhanced skin depo-
sition of FA compared to PBS saturated solution group
(CLT-3). There are two possible mechanisms responsi-
ble for the enhanced skin drug delivery via deformable
liposomes.3748 First, deformable liposomes may act as
drug carrier systems by which intact vesicles enter the SC
carrying vesicle-bound drug into or across the skin. Sec-
ond, vesicles may act as penetration enhancers, whereby
the vesicle lipid bilayers interact with the SC and sub-
sequently modify the intercellular lipid lamellae. Most
possibly, both mechanisms play a role in the enhanced
transdermal delivery of drugs by deformable liposomes
under non-occlusive conditions. It is possible that one of
the two mechanisms might predominate according to the
physicochemical properties of the drug considered.47
The improved permeation proﬁle and skin deposition
of FA from ethosomal formulations (ETS-2) could be
attributed to the lipid vesicle’s characteristics and some
kind of synergistic mechanism between ethanol, lipid
vesicles and skin lipids.144950 Firstly, the high concen-
tration of ethanol within ethosomes demonstrated some
ability to condense the size of the bilayer vesicles and
induced a charge transition from positive to negative,
which was a favorable physicochemical change for trans-
dermal penetration.51 Moreover, ethanol is a well-known
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permeation enhancer. The penetration enhancing effect of
ethanol can be attributed to two effects: (a) ‘Push effect:’
increased thermodynamic activity due to evaporation of
ethanol and improved solubility of solute such as that of
FA in this study; (b) ‘Pull effect:’ ethanol can interact
with intercellular lipid molecules in the polar head group
region, thereby increasing their ﬂuidity and decreasing the
density of the lipid multilayer, which results in an increase
in membrane permeability. Ethanol is also supposed to
extract the SC lipids52 lowering thereby the barrier func-
tion of the SC.
In addition, ethanol imparts ﬂuidity to the vesicle’s
bilayers, which in turn facilitates skin permeation. Further-
more, ethanol can act as a “blending” agent53 for lipid
vesicles, increasing their distribution in various skin lay-
ers. The ethanol effects can be followed by the interaction
between ethosomal vesicles and the skin. The ethosomal
vesicles behave as deformable liposomes and can interact
with the skin barrier to “forge” penetration or permeation
pathways by itself in the highly organized SC and ﬁnally
release drug at various points along the penetration path-
way as well as in deep skin layers.4754
On the other hand, the high ﬂux of ethosomes (ETS-2)
could be also due to high dosage of FA (18.0 mg/ml) in
this formulation, which arise from the enhanced solubility
of FA in the hydroethanolic system (2751± 021 mg/ml
(n= 3), ethanol 45%, v/v, at 25 C) as compared with that
of PBS saturated solution (736±023 mg/mL (n= 6)).
The deposition of FA in the skin attains for ethosomal
delivery values of 51.67 g/cm2, which can be related
(assuming a thickness of the heat-separated epidermis of
200 m) to a concentration of FA in the epidermis of about
13 mmol/L. This concentration is far above the minimal
effective concentration for e.g., antioxidant action of FA as
inhibiting lipid peroxidation.55 The obtained ﬂux through
the skin model may be sufﬁcient for systemic action espe-
cially in the light of the favorable pharmacokinetics (see
Introduction), but this needs to be evaluated in forthcom-
ing animal experiments, as many other parameters besides
the skin area treated determine the amount of drug reach-
ing the systemic circulation from the place of application.
5. CONCLUSION
In this study, different liposomal systems containing FA
have shown different abilities to deliver the drug across or
into skin. Moreover, the ethosomes containing relatively
high concentration of FA (ETS-2) delivered a signiﬁcantly
higher amount of FA across the skin and also lead to a
better epidermal skin deposition of the drug, which would
be sufﬁciently high for e.g., antioxidant effects. Therefore
ethosomes could be a promising carrier for enhanced skin
delivery of FA.
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Abstract: The aim of the present research is to evaluate the influence of different lipid vesicular 12 
systems as well as the effect of application mode on skin penetration and deposition behaviors of 13 
carboxyfluorescein (hydrophilic model drug) and Temoporfin (lipophilic model drug). All of the 14 
lipid vesicular systems, including conventional liposomes, invasomes and ethosomes, were 15 
prepared by film hydration method and characterized for particle size distribution, Ǯ-potential, 16 
vesicular shape and surface morphology, in vitro human skin penetration and skin deposition. 17 
Dynamic Light Scattering (DLS) and Transmission Electron Microscopy (TEM) defined that all of 18 
lipid vesicles had almost spherical structures with low polydispersity (PDI<0.2) and nanometric size 19 
range (z-average no more than 150 nm). In addition, all lipid vesicular systems exhibited a negative 20 
zeta potential. In vitro skin penetration and deposition experiments demonstrated that, in the case of 21 
CF with finite dose application (10 µL/cm2) and infinite dose application (160 µL/cm2), lipid vesicular 22 
systems, especially ethosomes and invasomes, compared with non-vesicular systems, can 23 
significantly improve the delivery of hydrophilic drug such as carboxyfluorescein into skin deep 24 
layers or across the skin. While in the case of mTHPC with finite and infinite dose application, most 25 
of drug accumulation was observed in the skin superficial layer for both lipid vesicular systems and 26 
non-vesicular systems. The results also revealed that the factors influencing the drug skin 27 
distribution concern the physicochemical characteristics of the drug, the choice of the vehicle 28 
formulation and the application mode applied.  29 
 30 
Keywords: Lipid vesicular systems, in vitro skin penetration and deposition, skin distribution, 31 
finite dose, infinite dose 32 
  33 
1. Introduction: 34 
Skin covers a surface area from 1.5 to 2.0 m2 and is regarded as the largest organ of the human 35 
body. From a pharmaceutical point of view, it offers a advantages over other routes of administration, 36 
including avoidance of first-pass metabolism, smaller fluctuations in plasma drug levels for 37 
repeated dosing, good patient compliance (Brown et al., 2006). However, although skin delivery 38 
systems may have the described advantages, most drugs are not amenable to this mode of 39 
administration because of the barrier function of the skin. Anatomically, the skin consists of three 40 
distinct layers, including stratum corneum (SC) having a thickness of 10–20 µm, viable epidermis 41 
(50–100 µm), and dermis (1–2 mm). The most simplistic organizational description of SC is 42 
suggested as the classic “brick-and-mortar” assembly with the corneocytes as the bricks and the 43 
intercellular lipids as the mortar (Elias, 1983). It is the “brick and mortar” architecture and lipophilic 44 
nature of the SC, which primarily accounts for the barrier properties of the skin (Elias, 1983).  45 
During the past decades, numerous techniques have been employed to overcome the barrier 46 
posed by the SC to improve transdermal drug delivery, one of which is the employment of lipid 47 
vesicular formulations as skin drug delivery systems to enhance drug transport across or into the 48 
skin barrier. Lipid vesicular systems such as conventional liposomes (Lasch and Wohlrab, 1986), 49 
transfersomes (Cevc, 1996; Cevc and Blume, 1992) and ethosomes (Touitou et al., 2000) offer a 50 
promising strategy for achieving the purpose of improved skin drug delivery. It should be pointed 51 
out that the great diversity of potential composition of these vesicles influences their 52 
physicochemical characteristics such as particle size, charge, thermodynamic phase and bilayer 53 
elasticity, which in turn have a significant effect on the interaction between vesicles and the skin and 54 
hence on the effectiveness of these vesicles as skin delivery systems. 55 
Moreover, the SC is also known to exhibit selective permeability with respect to the type of 56 
diffusing molecules, meaning that the barrier nature of the skin imposes physicochemical 57 
limitations to the type of permeants that can traverse the skin, including hydrophilicity, size, 58 
hydrogen-bonding ability and so on (Akomeah et al., 2007; Lian et al., 2008; Potts and Guy, 1992). 59 
On the other hand, drugs can be encapsulated and located at different positionsin the lipid vesicular 60 
system according to their lipophilicity. Hydrophilic drugs can be entrapped into the internal aqueous 61 
compartment, whereas amphiphilic, lipophilic and charged hydrophilic drugs can be associated with 62 
the vesicle bilayer. For these reasons, two model drugs, including Carboxyfluorescein (CF, Figure 1, 63 
hydrophilic molecule, LogPo/w= -1.5 (Nicole et al., 1989)) and Temoporfin (mTHPC, Figure 2, 64 
lipophilic one, LogPo/w= 9.24 (unpublished experimental data from our department)), were selected 65 
to assess and compare the skin penetration enhancing effect of different lipid vesicular systems on 66 
them. 67 
Furthermore, the enhancement effects and mechanisms of action of these lipid vesicular 68 
systems differ among the reports. The compositions of these formulation change due to penetration 69 
into the skin or evaporation of volatile components. These changes depend on the amount of 70 
liposome applied and occlusion conditions. Many studies have employed non-occluded conditions, 71 
but the application amount was varied. The amounts of formulation have ranged from 10µL/cm2 72 
(Dragicevic-Curic et al., 2008; Verma and Fahr, 2004) to 1.5mL/cm2 (Elsayed et al., 2007a). These 73 
differences may be related to variations in the observed effects of lipid vesicular systems, but there 74 
have been few reports aiming to clarify the effects of dose on lipid vesicular systems penetration. 75 
In this study, the influence of different lipid vesicular systems (including conventional 76 
liposomes, invasomes and ethosomes) as well as the effect of application mode (including finite 77 
dose application and infinite dose application) on skin penetration and deposition behaviors of CF 78 
and mTHPC has been investigated. This should provide an insight into the mechanisms of action of 79 
different lipid vesicular systems for model drugs with different physicochemical properties when 80 
different application modes are used.  81 
2. Materials and Methods 82 
2.1 Chemicals  83 
Lipoid S 100 (Phosphatidylcholine from soybean lecithin) was a gift from Lipoid GmbH, 84 
(Ludwigshafen, Germany). NAT 8539 (Soybean phosphatidylcholine (SPC) dissolved in ethanol 85 
containing: 77.3% phosphatidylcholine, 5% lysophosphatidylcholine, 3% cephaline and 1.1% 86 
phosphatidic acid of the dry residue) was purchased from Natterrmann Phospholipid GmbH, 87 
(Hermersberg, Germany). 5(6)-Carboxyfluorescein was a gift from Sigma-Aldrich, (Steinheim, 88 
Germany). Temoporfin (7,8-dihidro-5,10,15,20-tetrakis-(3-hydroxyphenyl) porphyrin, mTHPC) 89 
was a gift from biolitec AG, (Jena, Germany). Methanol (HPLC grade) was purchased from Carl 90 
Roth GmbH &Co. (Karlsruhe, Germany). DPPG (1, 2-dipalmitoylsn-glycero-3- 91 
phosphatidylglycerol) was purchased from Genzyme Pharmaceuticals, Sygena Facility, (Liestal, 92 
Switzerland). Bovine albumin serum (BSA), Limonene, Citral and Cineole were purchased from 93 
Sigma-Aldrich, (Steinheim am Albuch, Germany). And all other solvents used in this study were of 94 
analytical grade and were purchased from Merck (Darmstadt, Germany). 95 
2.2 Preparation of  lipid vesicles 96 
All the lipid vesicles were prepared by a conventional rotary evaporation method (Bendas and 97 
Tadros, 2007; Ita et al., 2007). Briefly, the appropriate weights of lipid or lipids (and with mTHPC in 98 
the case of lipid vesicles containing mTHPC) (the compositions of different vesicular systems 99 
shown in Table 1) were dissolved in methanol/chloroform solution (1:2, v/v) in round bottom flask. 100 
Thin lipid films were obtained by removing the organic solvents under vacuum condition (500 mbar 101 
10 min, 200 mbar 10 min, 100 mbar 10 min, 35 mbar 1 hr) at a temperature of 43 ºC with a rotary 102 
evaporator Type??. The resulted dry lipid films on the inside wall of round bottom flask were 103 
hydrated and dispersed with different hydration systems (and also containing CF in the case of  104 
lipid vesicles containing CF) corresponding to all formulations (Table 1) at room temperature. The 105 
obtained macroscopically homogenous solution was sonicated for totally 15 minutes in 3 cycles (5 106 
min for each cycle and 5 min pause among these cycles) with a sonication ice-water bath. Then 107 
these suspensions were extruded through polycarbonate membrane (diameter: 19 mm, pore 108 
diameter: 100 nm, Armatis, Schriesheim, Germany) 21 times to produce liposomes of the desired 109 
size with the help of a Hamilton-Bonaduz extruder (GASTIGHT#1001, Bonaduz, Switzerland) 110 
(MacDonald et al., 1991).  111 
Table 1 should be inserted here 112 
2.3 Characterization of lipid vesicular systems 113 
2.3.1 Particle size distribution and ζ-potential measurement 114 
The particle size, polydispersity index (PDI) and ζ-potential of all the lipid vesicles were 115 
determined by photon correlation spectroscopy (Zetasizer Nano series, Nano-ZS, Malvern 116 
Instruments Ltd., Worcestershire, UK). Before the size and ζ-potential measurements, different 117 
liposomes samples were diluted 100-times with PBS (pH 7.4, 10mM), which were also filtered 118 
through polycarbonate membrane (Minisart® syringe end filters 0.2 μm, Sartorius AG, Goettingen, 119 
Germany). Measurements were made at 25ഒ with a fixed angle of 137◦. Sizes quoted are the 120 
z-average mean for the liposomal hydrodynamic diameter (Nanda A, 2006). Calculation of 121 
ζ-potential (mV) was done by the instrument from electrophoretic mobility (Fang et al., 2008). 122 
2.3.2 Visualization by Cryo-Transmission Electron Microscopy 123 
The different lipid vesicles (CL, INS and ETS) were visualized by cryo-electron microscopy 124 
and their shape and lamellarity was investigated. 5 µL of test formulation were placed on a perforated 125 
copper grid (Quantifoil R 1.2/1.3) and excess liquid was blotted automatically for two seconds 126 
between two pieces of filter-paper-strips. Shortly after that, the samples were frozen by rapidly 127 
plunged in liquid ethane (cooled to -170 ~-180°C) in a cryo-box (Carl Zeiss NTS GmbH, 128 
Germany). Excess ethane was removed with a piece of filter paper in the cryo-box. The sample 129 
was transferred with the liquid nitrogen cooled holder (Gatan 626, USA) into the pre-cooled 130 
cryo-electron microscope (Philips CM 120, Netherlands) operated at 120 kV and viewed under 131 
low dose conditions. The Images were recorded with a 1k CCD Camera (FastScan F114, TVIPS, 132 
Gauting, Germany). 133 
2.4 In vitro skin penetration and deposition studies 134 
2.4.1 Skin preparation 135 
Female human abdominal skin from plastic surgery was used. The subcutaneous fatty tissue 136 
was removed from the skin by using a scalpel and surgical scissors and then frozen at -20 ºC with 137 
aluminum foil packed for later use in 3 months at most. Before use, the skin disks of 36mm were 138 
punched out, cleaned with PBS (pH 7.4, 50mM) and allowed to thaw with the stratum corneum (SC) 139 
side up open to the atmosphere and the dermal side bathed with receptor medium for overnight at 140 
4͠.After that the integrity of skin disks were checked with trans-epidermal water loss (TEWL) 141 
measurement (VapoMeter, Delfin Technology Ltd., Kuopio, Finland) to ensure that samples were 142 
free from any surface irregularity such as tiny holes or crevices in the portion that was used for skin 143 
penetration and deposition studies. 144 
2.4.2 Franz diffusion cell preparation  145 
In vitro skin penetration and deposition experiments of different liposomal systems containing 146 
mTHPC or CF were run in Franz diffusion cells non-occlusively and maintained at 37±1͠ 147 
throughout experiments, in order to maintain the skin surface at 32 ഒ. The effective penetration 148 
area and receptor cell volume are 3.14 cm2 and 15.0 ml, respectively. The acceptor compartment 149 
was filled with PBS buffer (pH 7.4, 50mM) as the receptor medium. Each test formulation was 150 
investigated in triplicate. Skin disks were mounted, with the SC side up and the donor compartment 151 
left dry and open to atmosphere for 0.5 hr before application of test formulation. Caution was taken 152 
to remove all air bubbles between the underside of the skin (dermis) and the acceptor solution. Also 153 
the skin was stretched in all directions to avoid the presence of furrows. In the case of finite dosage 154 
application, 10 µL/cm2 of the test formulation was applied to skin surface by a pipette and 155 
homogenously distributed by an inoculating loop (1 µL, VWR ® International, GmbH. Darmstadt, 156 
Germany). While in the case of infinite dosage application, 160µL/cm2 of the test formulation was 157 
applied using the same procedure. The experiments were carried out under non-occlusion with light 158 
protection. The incubation time of the skin with different test formulations was 12 h. At the end of 159 
experiment, a sample of 1 ml was withdrawn from the acceptor solution for the CF or mTHPC 160 
concentration measurement by fluorescence assay using a Fluostar (Optima Microplate Reader, 161 
BMG LABTECH GmbH. Offenburg, Germany). Then the formulations were removed from the 162 
skin by being washed five times with warm (45 ഒ) receptor medium. After cleaning, the skin was 163 
transferred for tape-stripping the SC.  164 
2.4.3 Stripping of the SC 165 
The stratum corneum (SC) was removed by striping with an adhesive tape (Cristall Klar Tesa®, 166 
Beiersdorf AG, Hamburg, Germany). In order to avoid any furrows, which could be a reason for 167 
false results of the stripping procedure, the skin was stretched and mounted with pins on cork discs 168 
mentioned previously. The skin was covered with a Teflon mask with a central hole of 15 mm in 169 
diameter. Each tape was put onto the skin and a weight of 2 kg was placed on the tape for 10 s. 170 
Afterwards the tape was rapidly removed with forceps and transferred into a glass vial of suitable 171 
size. Ten stripping procedures were performed consecutively. For analytical reasons, the stripped 172 
tapes were collected in vials according the following scheme: vial 1 included strip 1-5 with a code 173 
name as SC1-5, while vial 2 contained strip 6–10 and named after SC6-10. For extraction of CF from 174 
the adhesive tapes, 2 mL of a mixture solution of ethanol and PBS pH 7.4 (1:1, v/v) was added to 175 
each vial. In the case of mTHPC, 2 mL of methanol was used. Then these vials were shaken for 2h 176 
followed by vortex for 2min and sonication for another 2 min. The supernatant were withdrawn, 177 
diluted if necessary with methanol or the mixture solution of ethanol and PBS pH 7.4 (1:1, v/v) for 178 
mTHPC or CF, respectively, and analyzed by fluorescence measurement. 179 
2.4.4 Extraction of mTHPC or CF from deeper layers of the skin 180 
After the tape-stripping, the epidermis sheet was separated from the dermis with a surgical 181 
sterile scalpel. Afterwards dermis was cut into small pieces. Then the epidermis sheet and dermis 182 
pieces were transferred into special vials (Micro packaging Vials, 2mL, PeQLab Biotechnology 183 
GmbH, Erlangen, Germany). One vial was used for epidermis and nine vials for dermis, each of 184 
which was loaded with 0.55 g of ceramic beads inside (Zirconium oxide beads, 1.4 mm in diameter, 185 
Bertin Technology, Bad Wildbad, Germany). For extraction of mTHPC or CF from epidermis or 186 
dermis, 1 ml of methanol or the mixture solution of ethanol and PBS pH 7.4 (1:1, v/v) was added to 187 
each vial, respectively. The epidermis sheet and dermis pieces were micronized by Precellys S24 188 
(Bertin Technology, Bad Wildbad, Germany) with the following settings: 6000 rpm, 3 cycles, each 189 
one cycle for 30s. Afterwards the dispersions were ultra-centrifuged (10min., 13000 rpm, Minispin, 190 
Eppendorf, Germany) to subside skin tissue pieces at the bottom. The supernatant were withdrawn, 191 
diluted if necessary with the mixture solution of ethanol and PBS pH 7.4 (1:1, v/v) (in the case of 192 
mTHPC, methanol was used) and analyzed by fluorescence measurement.  193 
2.4.5 Fluorescent assay of CF and mTHPC 194 
The concentration of CF and mTHPC were determined by fluorescence spectroscopy method. 195 
Fluorescence detection was performed at an excitation of 485 nm and an emission of 520 nm in the 196 
case of CF while at an excitation of 390 nm and an emission of 645 nm in the case of mTHPC. The 197 
method was validated for linearity, accuracy and precision. The linear range during the 198 
measurements for CF and mTHPC was from 0.0005 µg/mL to 0.25 µg/mL (r=0.9998) and from 199 
0.015 µg/mL to 0.75 µg/mL (r=0.9997), respectively. The software used was Optima, version 2.10, 200 
BMG Lab Tech. 201 
2.5 Data analysis 202 
All reported data are meanrS.E.M. Statistical significance was checked by Student’s t-test 203 
and considered to be significant at P < 0.05, unless indicated. 204 
 205 
3. Results and discussion 206 
3.1 Particle size distribution and Ǯ-potential of lipid vesicular systems  207 
In this study, different lipid vesicular systems, including conventional liposomes, invasomes 208 
and ethosomes, were prepared and characterized in order to evaluate their capability to improve skin 209 
delivery of two model drugs, hydrophilic model drug CF and lipophilic model drug mTHPC. The 210 
compositions of these different lipid vesicular systems are reported in Table 1 and their 211 
corresponding results of particle size distribution and Ǯ-potential are summarized in Table 2.  212 
Conventional liposomes showed the largest mean vesicle size of 121.7±0.8 nm (n=3) and 213 
114.6±2.0 nm (n=3) for CF and mTHPC, respectively. Invasomes (115.3±1.4 (n=3) and 109.9±0.2 nm 214 
(n=3) in the case of invasomes containing CF and mTHPC, respectively) and ethosomes (81.6±5.8 215 
(n=3) and 77.8±0.5nm (n=3) in the case of ethosomes containing CF and mTHPC, respectively) had 216 
significantly (P<0.01) lower mean vesicle size relative to corresponding conventional liposomes. In 217 
the case of ethosomes, the presence of high concentration of ethanol (45%, v/v) could be the 218 
reasonable explanation about the reduced particle size of ethosomes in comparison with 219 
conventional liposomes. Ethanol could probably reduce the membrane thickness due to the 220 
formation of a phase with interpenetrating hydrocarbon chains (Barry and Gawrisch, 1994; Dubey 221 
et al., 2007). Furthermore, the addition of ethanol in phospholipid vesicles imparts negative charge 222 
to the formulation and this modification of net charge of the system confers lipid vesicles some 223 
degree of stearic stabilization and in turn lead to decrease in mean vesicle size (Jain et al., 2007). All 224 
of these mechanisms suggested that ethanol possesses some condensing ability for lipid vesicles. 225 
While, in the case of invasomes, the incorporation of 10% of ethanol could also reduce the particle 226 
size distribution with the same mechanism. Moreover, another important component, 227 
lysophosphatidylcholine (LPC) which was one of the components of NAT 8539 works as a 228 
surfactant  creating a high positive curvature in membranes (Fuller and Rand, 2001). However, the 229 
inclusion of 1% (w/v) terpenes mixture could lead to the increase of particle size distribution 230 
(Dragicevic-Curic et al., 2008). Regarding the polydispersity index (PDI), all the lipid vesicular 231 
systems showed low values (PDI<0.2), indicating that all of them were highly homogeneous 232 
suspensions.  233 
The ζ-potential is related to the charge on the surface of the vesicle which influences both 234 
vesicular properties such as stability, as well as skin–vesicle interactions. Conventional liposomes 235 
containing CF or mTHPC prepared in this study were found to possess a ζ-potential of -12.3±0.7 236 
mV (n=3) and -6.2±1.4 mV (n=3), respectively. Invasomes containing CF or mTHPC exhibited a 237 
negative ζ-Potential of -41.1±1.5 mV (n=3) and -39.4±1.2 mV (n=3), respectively. This result is 238 
unreasonable agreement with the recent research data on invasomes containing mTHPC from our 239 
department (Dragicevic-Curic et al., 2008, 2009). Ethosomes containing CF or mTHPC also 240 
showed a negative ζ-Potential of -79.7±1.4 mV (n=3) and -84.1±1.4 mV (n=3), respectively. In the 241 
case of ethosomes, incorporation of DPPG (Samad et al., 2007), is expected to produce highly 242 
negatively charged vesicles. The effect of surface charge of liposomes on the drug penetration has 243 
not been fully understood so far. Some researchers support the theory that the positive charges on 244 
the surface of liposomes could bind to negative charges of the SC enhancing thereby the drug 245 
penetration/permeation through the skin (Katahira et al., 1999; Song and Kim, 2006). However, 246 
other studies found that permeation of drugs through the skin is promoted by negatively charged 247 
vesicles (Ogiso et al., 2001; Sinico et al., 2005). According to the best of our knowledge, the surface 248 
charge of the vesicles will not only play a role on the interaction between skin and vesicles but also 249 
might contribute to the drug release from the vesicles. The drug release from vesicles in the stratum 250 
corneum is an important step which will affect transdermal flux (Honeywell-Nguyen and Bouwstra, 251 
2003). The rate and amount of released drug is a balance between two factors: (1) drug affinity to 252 
vesicles, and (2) drug solubility in lipids of the stratum corneum (Honeywell-Nguyen and Bouwstra, 253 
2003). In our previous study, another amphiphilic model drug, ferulic acid (FA), was used to 254 
investigate the effect of surface charge of liposomes on the drug skin permeation. This study (Chen 255 
et al., 2010) revealed that the flux of FA from negatively charged ethosomes is somewhat higher 256 
than from positively charged ethosomes, but without any significant difference. Since the pKa1 of 257 
FA is 4.52 (Erdemgil et al., 2007), it is negatively charged at pH 7.4. Therefore we suggested that FA 258 
could be retained in the positively charged vesicles, which in turn influences the skin penetration or 259 
permeation. In the case of CF, since it is also negatively charged at pH 7.4 (CF has a pKa of 6.3 260 
(Nicole et al., 1989)), we preferred to prepare the negatively charged lipid vesicles containing CF 261 
for comparison.. For the effect of positively charged liposomes and neutralized liposomes on the 262 
skin penetration and deposition of CF and mTHPC is investigated in a forthcoming study. 263 
Table 2 should be inserted here 264 
3.2 Morphology of different lipid vesicles 265 
Cryo-Transmission electron microscopy was used to visualize vesicles, and to study the shape 266 
and lamellarity of different lipid vesicles containing CF (Fig.3A) or mTHPC (Fig.3B). From the 267 
results, no matter if CF or mTHPC was encapsulated, the lipid vesicles had almost same shapes and 268 
structures. The vesicles of the conventional liposomes seemed to be unilamellar (Fig. 3a, b, g and h, 269 
black light arrows) and rarely bilamellar (Fig. 3a, b, g and h, black thick arrows), almost spherical 270 
and oval in shape, and some detected oligolamellar vesicles (Fig. 3a, b, g and h, white arrows). In 271 
the case of invasomes, the vesicles seemed to be almost unilamellar (Fig. 3c, d, i and j, black light 272 
arrow) and bilamellar (Fig. 3c, d, I and j black thick arrow). Regarding ethosomes, the vesicles 273 
appeared to be homogenously unilamellar (Fig. 3e, f, k and l, black light arrow).  274 
3.3 In vitro skin penetration and skin deposition studies 275 
3.3.1 Finite dose application for CF and mTHPC in vitro study 276 
Penetration and deposition data across full-thickness human skin with non-occlusive 277 
application of a finite dose (10µL/cm2) for CF or mTHPC after 12 hr by a range of formulation 278 
vehicles are shown in Table 3 and Table 4, respectively, with their distribution in different skin 279 
layers profiles shown in Figure 4 and Figure 5, respectively.  280 
Table 3 should be inserted here 281 
Table 4 should be inserted here 282 
In the case of CF, the highest CF accumulation from all the test formulations (Table 3) was 283 
found in the SC superficial layer (Stratum Corneum tape stripping layer Nr.1-5, SC L1-5) where 284 
ethosomes containing CF (CF-ETS) and hydroethanolic solution containing CF (the mixture 285 
solution of ethanol and PBS pH 7.4 (9:11, v/v), CF-HE) significantly enhanced CF accumulation in 286 
comparison with PBS (pH7.4) solution containing CF (CF-PBS) group (by a factor of 8.9 and 8.1, 287 
respectively, p < 0.01). Conventional liposomes containing CF (CF-CL) slightly improved CF 288 
accumulation in SC L1-5 in comparison with CF-PBS (by a factor of 1.5; p < 0.05).CF 289 
accumulations in SC deep layer (Stratum Corneum tape stripping layer Nr. 6-10, SC L6-10) and in 290 
epidermis were all improved when using all the lipid vesicular systems as well as CF-HE in 291 
comparison with CF-PBS, but with different magnitude . In the case of CF accumulation in SC 292 
L6-10, CF-ETS showed the highest potential, followed by CF-HE > CF-INS > CF-CL> CF-PBS. 293 
For CF accumulation in epidermis, both CF-ETS and CF-INS showed the highest CF accumulation 294 
in epidermis, followed by CF-CL > CF-HE > CF-PBS. CF accumulation in dermis was only 295 
significantly improved by CF-ETS in comparison with CF-PBS (by a factor of 2.2) and other 296 
formulations didn’t show any significant enhancement. Furthermore, no permeation of CF through 297 
the full thickness human skin was detected with this application condition from all the test 298 
formulation vehicles. 299 
Figure 4 should be inserted here 300 
In the case of mTHPC, the highest mTHPC accumulation from all the test formulations (Table 301 
4) was also found in the SC L1-5 where mTHPC-HE (hydroethanolic solution of ethanol and PBS 302 
pH 7.4 (6:4, v/v) containing mTHPC) showed the highest mTHPC accumulation, followed by 303 
mTHPC-CL> mTHPC-ET> mTHPC-ETS> mTHPC-INS. Regarding mTHPC accumulation in SC 304 
L6-10 and in epidermis, mTHPC-HE also showed the highest potential, but followed by different 305 
orders: mTHPC-CL> mTHPC-ETѩmTHPC-ETS≥ mTHPC-INS and mTHPC-ETS> mTHPC-ETѩ306 
mTHPC-INS≥ mTHPC-CL, respectively. The comparison of these five formulations showed that 307 
significant differences existed between mTHPC-HE and others (p< 0.01) regarding the mTHPC 308 
accumulation in these three different skin layers. However, the permeation of mTHPC through the 309 
full thickness human skin and mTHPC accumulation in dermis were not detected with this 310 
application condition for all test formulations. 311 
Figure 5 should be inserted here 312 
As can be seen, significant differences can be found between lipid vesicular systems containing 313 
CF and mTHPC with respect to drug skin distribution profile of CF or mTHPC. In the case of 314 
mTHPC, most of mTHPC can be found in SC superficial layers (SC L1-5) (Figure 5 and Table 4). 315 
The percentage of mTHPC present in SC L1-5 was 94.0%, 84.8% and 92.6% of the total mTHPC 316 
delivered for conventional liposomes (mTHPC-CL), invasomes (mTHPC-INS) and ethosomes 317 
(mTHPC-ETS), respectively. While, in the case of CF, even though the highest drug accumulation 318 
was also found in SC L 1-5, the drug skin distribution differed a lot according to the lipid vesicles 319 
applied (Figure 4 and Table 3). The percentage of CF present in SC L1-5 was 51.4%, 30.9% and 320 
54.1% of the total CF delivered for conventional liposomes (CF-CL), invasomes (CF-INS) and 321 
ethosomes (CF-ETS), respectively.   322 
In order to explain this drug skin distribution difference, it is necessary to consider possible 323 
mechanisms of action of different lipid vesicular systems. Conventional liposomes were expected to 324 
be effective at delivering drugs into the upper layers of the skin. It is agreed in the recent literature 325 
that in most cases conventional liposomes are not penetrating the skin but remain confined to upper 326 
layers of the SC or form a deposit on the surface of the skin (Tanner and Marks, 2008). The 327 
penetration properties of conventional liposomes may fall into one of two possible categories, 328 
including the penetration enhancing effect and vesicle adsorption to and/or fusion with the SC (El 329 
Maghraby et al., 2006). The first possible mode of action that was described firstly in 1987 (Kato et 330 
al., 1987) and supported by others (Hofland et al., 1995; Kirjavainen et al., 1999; Zellmer et al., 331 
1995). This mode suggests that liposomal lipids may act as penetration enhancers, thereby 332 
loosening the lipid structure of the SC and promoting an impaired barrier function (Kirjavainen et al., 333 
1999). The second possible mode for conventional liposomes is adsorption to and/or fusion with the 334 
SC (Abraham and Downing, 1990; Hofland et al., 1995; Kirjavainen et al., 1996), suggesting that 335 
the liposomal lipids penetrate into the SC by adhering onto the surface of the skin and subsequently 336 
destabilizing and fusing or mixing with the lipid matrix (Kirjavainen et al., 1996). However, the 337 
collapse of vesicles on skin surface may form an additional barrier, reducing the permeation of 338 
hydrophilic molecules encapsulated in the vesicular aqueous core (Elsayed et al., 2007b).  339 
Regarding invasomes (belonging to the class of deformable liposomes) due to the presence of 340 
lysophosphatidylcholine (LPC) and ethanol and terpenes (Dragicevic-Curic et al., 2008; Verma and 341 
Fahr, 2004). Hence, there are two possible mechanisms responsible for its enhanced skin drug 342 
delivery (Dragicevic-Curic et al., 2008). First, invasomes may act as drug carrier systems by which 343 
intact vesicles can enter the SC carrying vesicle-bound drug into or across the skin. Second, 344 
invasomes may act as penetration enhancers, whereby the vesicle lipid bilayers interact with the SC 345 
and subsequently modify the intercellular lipid lamellae. It may also possible that one of the two 346 
mechanisms might predominate according to the physicochemical properties of the drug considered 347 
(Elsayed et al., 2007b). 348 
The enhancing effect of ethosomes could be attributed to the synergistic mechanism between 349 
ethanol, lipid vesicles and skin lipids (Dayan and Touitou, 2000; Elsayed et al., 2006; Touitou et al., 350 
2000). Firstly, ethanol is a well-known permeation enhancer. The penetration enhancing effect of 351 
ethanol can be attributed to two effects: (a) ‘Push effect’: increased thermodynamic activity due to 352 
evaporation of ethanol and improved solubility of solute in this study; (b) ‘Pull effect’: ethanol can 353 
interact with intercellular lipid molecules in the polar head group region, thereby increasing their 354 
fluidity and decreasing the density of the lipid multilayer, which results in an increase in membrane 355 
permeability. Ethanol is also supposed to extract the SC lipids (Bach and Lippold, 1998) lowering 356 
thereby the barrier function of the SC. In addition, ethanol imparts fluidity to the vesicle's bilayers, 357 
which in turn facilitates vesicles skin permeation. Furthermore, ethanol can act as ǎ blending” agent 358 
for lipid vesicles with increasing their distribution in various skin layers (Panchagnula et al., 2005). 359 
The ethanol effects can be followed by the interaction between ethosomal vesicles and the skin. The 360 
ethosomal vesicles may also behave as deformable liposomes and can interact with the skin barrier 361 
to “forge” penetration or permeation pathways by itself in the highly organized SC and finally 362 
release drug at various points along the penetration pathway as well as in deep skin layers (Elsayed 363 
et al., 2007b; Godin and Touitou, 2003). 364 
Moreover, the different molecular mechanisms by which the diffusion through the stratum 365 
corneum of hydrophilic molecule (CF) and lipophilic molecule (mTHPC) should be also taken into 366 
account, because drug skin penetration and deposition via lipid vesicular systems involves several 367 
processes, including interaction between SC and lipid vesicles, partitioning of the drug from its lipid 368 
vesicular system to the skin and the following drug diffusion in the skin. Drugs are considered to 369 
penetrate through the skin by one of three pathways: the polar, non-polar, or polar/non-polar route 370 
depending on their physicochemical properties, in which logPo/w of drugs is thought to be the key 371 
factor (Verma and Fahr, 2004). The logPo/w value, which is a measure of how well a substance 372 
partitions between a lipid and water, determines the route of drug penetration through the skin. 373 
Temoporfin (mTHPC), which is highly lipophilic, is expected to penetrate the skin by non-polar 374 
pathways, whereas CF, which is hydrophilic, should utilize the polar pathways. The intrinsic 375 
permeability of both hydrophilic and lipophilic penetrants is governed by the composition of the 376 
skin, with the former limited by their partitioning into the lipophilic SC and the latter, by 377 
partitioning from the SC into the less lipophilic epidermis (Nicoli et al., 2008; Zhang et al., 2010). 378 
Consequently, the logPo/w value of drug molecule has an effect on the enhancement efficacy of 379 
penetration enhancers. Hydrophilic molecules such as CF, owing to their low partition coefficient 380 
and high hydrogen-bonding potential, would show a dramatic increase in permeation with suitable 381 
enhancers, however, lipophilic molecules which move with relative ease through the SC do not have 382 
the same opportunity to act as indicators of enhancement (Barry and Bennett, 1987; Verma and Fahr, 383 
2004; Zhang et al., 2010). 384 
From all the discussion above, lipid vesicular systems including conventional liposomes, 385 
invasomes (deformable liposomes) and ethosomes can act as penetration enhancers to improve the 386 
skin drug delivery by their vesicle lipid bilayers or their additives such as ethanol and terpenes 387 
interacting with the SC and subsequently modifying the SC intercellular lipid lamellae. However, 388 
this penetration enhancing effect of lipid vesicular systems could play a much more important role 389 
in the enhanced skin delivery of hydrophilic drug such as CF than in the case of lipophilic drug such 390 
as mTHPC because this penetration enhancing effect just increases the partitioning of CF into the 391 
lipophilic SC but does not really increase the partitioning of mTHPC from the SC into the less 392 
lipophilic epidermis. Hence, for a lipophilic drug such as mTHPC, the entrapment of the drug in 393 
vesicular lipid bilayers and intact vesicles penetration could be crucial for optimum skin deposition 394 
and transdermal permeation. From this point of view, it is almost impossible for conventional 395 
liposomes to reach this aim. For deformable liposomes such as invasomes and ethosomes, it is 396 
possible for both of them to achieve this purpose because they somehow can act as drug carrier 397 
systems, whereby intact vesicles enter the SC carrying vesicle-bound drug molecules into the skin. 398 
However, for deformable liposomes such as invasomes, it should be pointed out that the driving 399 
force for them entering the skin is xerophobia which is the tendency to avoid dry surroundings of 400 
water-“loving” phospholipids (Cevc and Blume, 1992) and recent evidence showed that the water 401 
gradient across the skin may not be linear and there may be a relatively ‘dry’ region within the 402 
stratum corneum . It was also noticed that even in fully hydrated state, the water content in the 403 
lowest stratum corneum layers close to the viable epidermis is much lower than in central regions of 404 
the stratum corneum (Williams, 2003). Therefore, it was expected that, as a result of the osmotic 405 
force, deformable liposomes will not penetrate beyond the level of the lowest layers in stratum 406 
corneum. Regarding ethosomes, from the results of this study, it is also not very successful to deliver 407 
mTHPC into deeper layers of skin. Therefore, other or better designed carrier systems for mTHPC 408 
should be developed.  409 
Another important technology which can also improve significantly the skin delivery for both 410 
CF and mTHPC is the application of hydroethanolic solution (Table 1, CF-HE and mTHPC-HE). 411 
From the results, in the case of CF, CF-HE significantly increased the CF accumulation in SC layers 412 
(SC L1-5 and SC L6-10) compared with all other formulations containing CF except CF-ETS. 413 
While, in the case of mTHPC, mTHPC-HE showed the highest mTHPC accumulation in both SC 414 
layers and epidermis compared with all other formulation containing mTHPC. There are two 415 
reasonable explanations responsible for its enhanced drug skin delivery effect. The first one is the 416 
penetration enhancing effect by ethanol, which has been already described in detail above. The 417 
second one is the increased thermodynamic activity of drugs due to the incorporation of ethanol or 418 
water. In the case of CF, because it is hydrophilic and has a lower solubility in ethanol than  in water, 419 
the incorporation of ethanol in water will increase the thermodynamic activity of CF compared with 420 
aqueous solution containing the same concentration of CF such as CF-PBS, CF-CL and CF-INS 421 
Both CF-ETS and CF-HE could significantly (p<0.01) increase the CF accumulation in SC 422 
compared to the  other formulations. Moreover, because the synergistic penetration enhancing 423 
effect between ethanol, lipid vesicles and the possible intact vesicle penetration mechanism of 424 
ethosomes, CF-ETS also showed the highest CF accumulation in epidermis and dermis compared 425 
with all others. In the case of mTHPC, the situation is different. Because mTHPC is highly 426 
lipophilic and its low solubility in water, the incorporation of water in ethanol will increase its 427 
thermodynamic activity compared with ethanol solution containing the same concentration of 428 
mTHPC such as mTHPC-ET. For the lipid vesicular systems containing mTHPC in this study, even 429 
though high water amounts are involved (see Table 1), entrapment of mTHPC in the lipid bilayers, 430 
in fact, solubilizes mTHPC. Hence, the thermodynamic activity of mTHPC of these systems is not 431 
equally increased compared with mTHPC-HE, which explains why mTHPC-HE showed the best 432 
potential of improving mTHPC skin delivery. 433 
3.3.2 Infinite dose application for CF and mTHPC in vitro study 434 
Full-thickness human skin penetration and deposition data for application of an infinite dose 435 
(160µL/cm2) for CF or mTHPC after 12 hr non-occlusive treatment with a range of formulation 436 
vehicles are shown in Table 5 and Table 6, respectively, with their distribution in different skin 437 
layers profiles shown in Figure 6 and Figure 7, respectively.  438 
Table 5 should be inserted here 439 
Table 6 should be inserted here 440 
In the case of CF, the highest CF accumulation from all the test formulations (Table 5) was 441 
found in the SC L1-5 where CF accumulation decreased in the following order: CF-ETS > CF-HE >> 442 
CF-CL > CF-INS > CF-PBS. CF accumulation in SC L1-5 was significantly improved by CF-ETS 443 
and CF-HE compared with CF-PBS (by a factor 33.9 and 17.9, respectively, p <0.01), while CF-CL 444 
and CF-INS also significantly improved CF accumulation in SC L1-5 compared with CF-PBS, but 445 
to a smaller extent (by a factor of 3.8 and 1.9, respectively, p <0.01). CF accumulation in SC L6-10 446 
was significantly improved by CF-ETS compared with CF-PBS (by a factor 63.3, p <0.01), while 447 
CF-HE, CF-INS and CF-CL also significantly improved CF accumulation in SC L6-10 compared 448 
with CF-PBS, but to a smaller extent (by a factor of 7.0, 3.5 and 5.0, respectively, p <0.01). For 449 
epidermis and dermis, CF accumulation decreased in the same following orders: CF-ETS >> 450 
CF-INS > CF-HE > CF-CL > CF-PBS. When compared with CF-PBS, CF accumulation both in 451 
epidermis and in dermis were significantly improved by CF-ETS (by a factor 26.7 and 13.8, 452 
respectively, p <0.01) and by CF-INS (by a factor 3.0 and 2.1, respectively, p <0.01). While CF 453 
accumulation both in epidermis and in dermis were also improved, but to a small extent, by CF-HE 454 
(by a factor of 2.1 and 1.7, respectively, 0.05<p<0.1) and by CF-CL (by a factor of 1.7 and 1.5, 455 
respectively, 0.05<p<0.1). CF permeated through the full thickness skin (CF in receptor fluid) can 456 
be found from all the tested formulations. However, the concentration of CF in receptor fluid from 457 
CF-PBS and CF-HE were too low and out of the linear range of CF for the fluorescent detector. For 458 
this reason, the CF in receptor fluid were only calculated from lipid vesicular systems and had a 459 
following order: CF-ETS > CF-INS > CF-CL. Moreover, from the results, CF across the 460 
full-thickness skin from CF-ETS, CF-INS and CF-CL accounted for quite a small percentage of the 461 
total CF delivered into skin, only 1.5%, 2.1% and 1.1%, respectively. 462 
Figure 6 should be inserted here 463 
In the case of mTHPC, the highest mTHPC accumulation from all the test formulations (Table 464 
6) was still found in the SC L1-5 where mTHPC-HE showed the highest mTHPC accumulation, 465 
followed by mTHPC-ETS> mTHPC-CL> mTHPC-ET> mTHPC-INS. However, regarding 466 
mTHPC accumulation in SC L6-10 and in epidermis, mTHPC-ET showed the highest potentials, 467 
but followed by different orders: mTHPC-HE> mTHPC-CLѩmTHPC-ETS≥ mTHPC-INS and 468 
mTHPC-ETS> mTHPC-CLѩmTHPC-HE≥ mTHPC-INS for SC L6-10 and epidermis, respectively. 469 
Both the permeation of mTHPC through the full thickness human skin and mTHPC accumulation in 470 
dermis were still not detected with this application condition from all the tested formulations. 471 
Figure 7 should be inserted here 472 
From these results,, with an infinite dose application, most of mTHPC delivered into skin was 473 
still inclined to be deposited in superficial layers of SC (Table 6 and Figure 7), while much more 474 
percentage of CF could be delivered into deeper layers of skin, especially by lipid vesicular systems, 475 
but with different extents (Table 5 and Figure 6). In the case of CF-CL, with an infinite dose applied, 476 
the radio between CF accumulation in SC L 1-5 and in SC L6-10 significantly decreased compared 477 
with a finite dose applied, which means more percentage of CF was delivered into SC deeper layers. 478 
The reason for this could be that the application of an infinite dose in donor compartment will form 479 
a thick liquid formulation layer covering on the skin surface with a height of 1.6mm (calculated 480 
value), while a finite dose just can form a thin layer of only 0.1mm (calculated value). This will in 481 
turn result in much higher hydration condition of the skin with an infinite dose than with a finite 482 
dose. This increased skin hydration facilitated the interaction between conventional liposomes and 483 
skin, which in turn increased the CF penetration into SC deeper layers. Moreover, in the case of 484 
CF-CL, with a finite dose applied, the CF delivered into the skin deep layer (including CF 485 
accumulated in epidermis, dermis and receptor phase) was 42.6% from the amount delivered into 486 
the skin; while, with an infinite dose applied, it decreased to 18.4%. However, in the case of 487 
mTHPC-CL, with a finite dose applied, the mTHPC delivered into the skin deep layer was only 488 
1.9%; while, with an infinite dose applied, it increased to 4.4%. As mentioned before, according to 489 
the mechanism of action of conventional liposomes, this reason could be that the collapse of vesicles 490 
on skin surface may form an additional barrier, reducing the permeation and penetration of 491 
hydrophilic molecules such as CF encapsulated in the vesicular aqueous core (Elsayed et al., 492 
2007b).  493 
In the case of CF-INS, with an infinite dose application, the ratio between CF accumulation in 494 
SC and in skin deep layers significantly increased compared with a finite dose applied, which means 495 
less percentage of CF was delivered into skin deep layers. With a finite dose applied, the CF 496 
delivered into the skin deep layer (including CF accumulated in epidermis, dermis and receptor 497 
phase) was 52.9%; while, with an infinite dose applied, it decreased to 37.8%. In the case of 498 
mTHPC-INS, there was a similar trend. With a finite dose applied, the mTHPC delivered into the 499 
skin deep layer was 8.8%; while, with an infinite dose applied, it decreased to 6.1%. Considering 500 
one of possible mechanisms of action of invasomes, with a thick formulation liquid layer covering 501 
on the skin surface formed by an infinite dose, invasomes which are regarded as deformable 502 
liposomes could lose its penetration driving force because of the disappearance of the 503 
trans-epidermal osmotic gradient in this application mode. Hence, less percentage of CF and 504 
mTHPC could be delivered into skin deep layers with infinite dose application. On the other hand, 505 
in the case of CF-INS, with a finite dose applied, the CF skin delivery enhancement ratio between 506 
CF-INS and CF-PBS was a factor of 1.4; while, with an infinite dose applied, it increased to a factor 507 
of 2.4.This result suggested another possible the mechanism of action of invasomes: one part of the 508 
vesicles is fragmented during their penetration into the upper skin layers, the released terpenes, as 509 
well as phospholipids, act also as penetration enhancers fluidizing the intercellular lipids 510 
(Dragicevic-Curic et al., 2008), which improves the drug skin delivery. Therefore, all these results 511 
from this study supported the hypothesis, our department suggested before, on mechanism of action 512 
of invasomes: some of the invasomes were fragmented during their penetration through the SC, 513 
while some of the small and deformable invasomes could have penetrated to the deeper SC layers 514 
intact (Dragicevic-Curic et al., 2008). 515 
In the case of CF-ETS, with an infinite dose application, the radio between CF accumulation in 516 
SC and in deeper skin layers (including in epidermis and in dermis as well as in receptor fluid) 517 
significantly decreased compared with a finite dose applied, which means much more percentage of 518 
CF was delivered into skin deeper layers and across the skin. With a finite dose applied, the CF 519 
delivered into the skin deep layer (including CF accumulated in epidermis, dermis and receptor 520 
phase) was 11.7%; while, with an infinite dose applied, it increased to 20.7%. In the case of 521 
mTHPC-INS, there was also a similar trend. With a finite dose applied, the mTHPC delivered into 522 
the skin deep layer was 4.4%; while, with an infinite dose applied, it increased to 6.1%.Increased 523 
skin hydration could also be responsible for this. Another important reason could be different 524 
amount of ethanol in this two application mode. With a finite dose application, because of the small 525 
amount of ethanol applied, the evaporation of ethanol is much quicker than with an infinite dose 526 
applied. This means that more ethanol could interact with skin and lipid vesicles with an infinite 527 
dose applied, which in turn improved the CF penetration into deeper skin layers or across the skin.  528 
Furthermore, with a finite dose application, a low CF accumulation in SC layers for CF-INS 529 
compared with CF-ETS can be found, however, a similar CF accumulation in epidermis. The reason 530 
might be that CF-INS penetrates faster through the deeper layers in the SC than CF-ETS due to 531 
different mechanisms of action between them. There is another thing should be pointed out that an 532 
infinite dose of mTHPC-ET resulted in a significant increase of percentage of mTHPC delivered 533 
into SC L6-10 and epidermis. This could be explained by the long contact time (12 hrs) with ethanol, 534 
impairing the skin structure.  535 
 536 
Moreover, a comparison of an infinite dose and a finite dose under non-occlusive application for CF 537 
and mTHPC revealed that the total amount of both of them delivered into skin were significantly 538 
increased when an infinite dose applied, but to a significantly different extent. In the case of CF, 539 
total amount of CF delivered into skin with a finite dose (10µl/cm2) ranged from 0.047±0.010 540 
µg/cm2 (CF-PBS) to 0.401±0.045 µg/cm2 (CF-ETS), while with an infinite dose (160µl/cm2) from 541 
0.327±0.107 µg/cm2 (CF-PBS) to 10.837±1.210 µg/cm2 (CF-ETS). Therefore, with increasing 542 
dosage of formulation from a finite dose to an infinite dose, total amount of CF delivered into skin 543 
increased by from 6.9 times (CF-PBS) to 27.0 times (CF-ETS). However, in the case of mTHPC, 544 
total amount of mTHPC delivered into skin with a finite dose (10µl/cm2) ranged from 0.079±0.024 545 
µg/cm2 (mTHPC -INS) to 0.483±0.073 µg/cm2 (mTHPC -HE), while with an infinite dose 546 
(160µl/cm2) from 0.312±0.035 µg/cm2 (mTHPC -INS) to 0.956±0.003 µg/cm2 (mTHPC -HE). 547 
Hence, with the same situation, total amount of mTHPC delivered into skin only increased by 548 
from1.9 times (mTHPC -HE) to 3.9 times (mTHPC -INS). There could be two possible reasons 549 
responsible for this. The first one is that the increased skin hydration effect rooted from a thick 550 
liquid formulation layer covering on the skin surface formed by an infinite dose applied in donor 551 
compartment. Generally, increased tissue hydration appears to increase transdermal delivery of both 552 
hydrophilic and low lipophilic compounds due to an increase in partition into the skin of drugs 553 
(Williams and Barry, 2004). It is proposed that the hydration effect of them on the stratum corneum 554 
could make the penetration of hydrophilic drugs easier. However, for the high lipophilic compounds 555 
(log Po/w>2), partition into thěhydrated” stratum corneum are made difficult, consequently, which 556 
results in a reduction in their permeation capacity through the skin (Zhang et al., 2010). Another 557 
possible reason could be the different molecular mechanisms by which the diffusion through the 558 
stratum corneum of CF and mTHPC, which has already been discussed above. With an infinite dose 559 
of formulation applied on the skin, the modification of the micro-structure of SC could be reinforced 560 
compared with a finite dose applied. This will facilitate the skin penetration and deposition of CF 561 
because the limited step for skin penetration of CF is its partitioning into SC from formulation. 562 
However, due to the limited step for mTHPC is their partitioning from the SC into the less lipophilic 563 
epidermis, the augmented modification of the micro-structure of SC by an infinite dose could not 564 
result in the same enhancing effect for mTHPC as for CF. 565 
 566 
4.  Conclusion  567 
In this study different lipid vesicular systems including conventional liposomes, invasomes 568 
and ethosomes containing CF or mTHPC were developed and characterized. In vitro human 569 
full-thickness skin penetration studies revealed that, in the case of CF with finite dose application 570 
(10 µL/cm2), the highest drug accumulation in epidermis was observed from CF-INS as well as 571 
CF-ETS. The drug accumulation in dermis was only significantly improved by CF-ETS in 572 
comparison with CF-PBS. There was no CF detected in receptor phase. While in the case of CF with 573 
infinite dose application (160 µL/cm2), the highest drug accumulation both in epidermis and in dermis 574 
was observed from CF-ETS. CF also could be detected in the receptor phase from all lipid vesicular 575 
systems with such an order: CF-ETS > CF-INS> CF-CL. On the other hand, in the case of mTHPC 576 
with finite and infinite dose application, most of drug accumulation was observed in skin superficial 577 
layer from both lipid vesicular systems and non-vesicular systems, but with different orders. There 578 
was no mTHPC detected in dermis and in receptor phase from all the tested formulations. ..  The 579 
results suggested that lipid vesicular systems are more effective for improving the penetration and 580 
deposition of hydrophilic drugs such as CF than for lipophilic drugs such as mTHPC. In order to 581 
confirm this point, further studies with more different model drugs and different kind of lipid 582 
vesicular systems involved are needed. Moreover, the composition of lipid vesicular systems also 583 
played a significant role on drug skin distribution for the hydrophilic drugs such as CF, but not for 584 
lipophilic drugs such as mTHPC. From the results, we also found that the application mode (finite or 585 
infinite dose application) not only had a direct action on the drug skin penetration and deposition, 586 
but also could affect the degree of hydration of the SC and the possible mechanism of some lipid 587 
vesicular system which in turn influence the drug skin distribution.  588 
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Legends to Figures 706 
 707 
 708 
Fig.1. Structure of 5(6)-Carboxyfluorescein 709 
 710 
Fig.2. Structure of Temoporfin 711 
 712 
Fig.3A. Visualization of different liposomal systems containing CF by 713 
cryo-transmission electron microscopy.  714 
(a, b) conventional liposomes containing 5.0mg/ml of CF; (c, d) invasomes containing 715 
5.0mg/ml of CF; (e, f) ethosomes containing 5.0 mg/ml of CF. Black light arrows 716 
represent unilamellar vesicles; black thick arrows represent bilamellar vesicles, while 717 
white thick arrows represent oligolamellar vesicles.  718 
 719 
Fig.3B. Visualization of different liposomal systems containing mTHPC by 720 
cryo-transmission electron microscopy. (g, h) conventional liposomes containing 721 
1.5mg/ml of mTHPC; (i, j) invasomes containing 1.5mg/ml of mTHPC;  722 
(k, l) ethosomes containing 1.5mg/ml of mTHPC. Black light arrows represent 723 
unilamellar vesicles; black thick arrows represent bilamellar vesicles, while white thick 724 
arrows represent oligolamellar vesicles.  725 
 726 
Fig.4. Skin penetration and deposition of CF in different skin layer via full-thickness 727 
human skin from different formulations with finite dosage application (10µl/cm2) after 728 
12hr. Note: CF-CL: Conventional liposomes containing CF (5.0mg/ml); CF-INS: 729 
Invasomes containing CF (5.0mg/ml); CF-ETS: ethosomes containing CF (5.0mg/ml); 730 
CF-PBS: PBS (pH7.4) containing CF (5.0mg/ml); CF-HE: Hydroethanolic mixture 731 
solution of ethanol and PBS pH 7.4 (9:11, v/v) containing CF (5.0mg/ml). Values 732 
represent mean ± SD (n=3) 733 
 734 
Fig.5. Skin penetration and deposition of mTHPC in different skin layer via 735 
full-thickness human skin from different formulations with finite dosage application 736 
(10µl/cm2) after 12hr. Note: mTHPC-CL: Conventional liposomes containing mTHPC 737 
(1.5mg/ml); mTHPC-INS: Invasomes containing mTHPC (1.5mg/ml); mTHPC-ETS: 738 
Ethosomes containing mTHPC (1.5mg/ml); mTHPC-ET: Ethanol solution containing 739 
mTHPC (1.5mg/ml). mTHPC-HE: Hydroethanolic mixture solution of ethanol and 740 
PBS pH 7.4 (6:4, v/v) containing mTHPC (1.5mg/ml). Values represent mean ± SD 741 
(n=3) 742 
 743 
Fig.6. Skin penetration and deposition of CF in different skin layer via full-thickness 744 
human skin from different formulations with infinite dosage application (160µl/cm2) 745 
after 12hr. Note: CF-CL: Conventional liposomes containing CF (5.0mg/ml); CF-INS: 746 
Invasomes containing CF (5.0mg/ml); CF-ETS: ethosomes containing CF (5.0mg/ml); 747 
CF-PBS: PBS (pH7.4) containing CF (5.0mg/ml); CF-HE: Hydroethanolic mixture 748 
solution of ethanol and PBS pH 7.4 (9:11, v/v) containing CF (5.0mg/ml). Values 749 
represent mean ± SD (n=3) 750 
 751 
Fig.7. Skin penetration and deposition of mTHPC in different skin layer via 752 
full-thickness human skin from different formulations with infinite dosage application 753 
(160µl/cm2) after 12hr. Note, CL: Conventional liposomes containing mTHPC 754 
(1.5mg/ml); INS: Invasomes containing mTHPC (1.5mg/ml); ETS: Ethosomes 755 
containing mTHPC (1.5mg/ml); CTL-1: Control group 1 Ethanol solution containing 756 
mTHPC (1.5mg/ml). Values represent mean ± SD (n=3) 757 
 758 
Tables 
 
 
 
Table 1: Composition of different lipid vesicular systems and control groups 
 
Code Lipids and other components  Drug Solvent system 
CF-CLa Lipoid-S100, 40.0 mg/ml 
Cholesterol, 3.0 mg/ml 
CF 
5.0 mg/ml 
PBS (pH 7.4)  
 
CF-INSb 
 
NAT8539, 133.0 mg/ml 
Terpenesk, 10.0 mg/ml 
CF 
5.0 mg/ml 
PBS (pH 7.4) 
Ethanol (10%, v/v) 
CF-ETSc Lipoid-S100, 40.0 mg/ml 
DPPG, 4.0mg/ml 
CF 
5.0 mg/ml 
PBS (pH 7.4) 
Ethanol (45%, v/v) 
mTHPC-CLd Lipoid-S100, 40.0 mg/ml 
Cholesterol, 3.0 mg/ml 
mTHPC 
1.5mg/ml 
PBS (pH 7.4)  
 
mTHPC-
INSe 
NAT8539, 133.0 mg/ml 
Terpenesk, 10.0 mg/ml 
mTHPC 
1.5mg/ml 
PBS (pH 7.4) 
Ethanol (10%, v/v) 
mTHPC-
ETSf 
Lipoid-S100, 40.0 mg/ml 
DPPG, 4.0mg/ml 
mTHPC 
1.5mg/ml 
PBS (pH 7.4) 
Ethanol (45%, v/v) 
CF-PBSg - CF 
5.0 mg/ml 
PBS (pH 7.4) 
 
CF-HEh - CF 
5.0 mg/ml 
PBS (pH 7.4) 
Ethanol (45%, v/v) 
mTHPC-ETi - mTHPC 
1.5mg/ml 
Ethanol 
 
mTHPC-HEj 
 
- mTHPC 
1.5mg/ml 
PBS (pH 7.4) 
Ethanol (60%, v/v) 
 
Note: a Conventional liposomes containing CF; b Invasomes containing CF; c Ethosomes containing CF;  
d Conventional liposomes containing mTHPC; e Invasomes containing mTHPC; f Ethosomes containing mTHPC; 
g PBS (pH7.4) containing CF; h Hydroethanolic solution containing CF (the mixture solution of ethanol and PBS 
pH 7.4 (9:11, v/v)); i Ethanol solution containing mTHPC; i Hydroethanolic solution containing mTHPC (the 
mixture solution of ethanol and PBS pH 7.4 (6:4, v/v)); k Terpenes mixture (Limonene: citral: cineole=1:4.5:4.5, 
v/v) 
 
  
Table(s)
Table 2: Characterization of different lipid vesicular systems 
  
Code Particle size (nm)  PDIg ζ-potential (mV) 
CF-CLa 121.7±0.8 0.159±0.015 -12.3±0.7 
CF-INSb 115.3±1.4 0.110±0.011 -41.1±1.5 
CF-ETSc 81.6±5.8 0.161±0.007 -79.7±1.4 
mTHPC-CLd 114.6±2.0 0.149±0.008 -6.2±1.4 
mTHPC-INSe 109.9±0.2 0.076±0.005 -39.4±1.2 
mTHPC-ETSf 77.8±0.5 0.130±0.012 -84.1±1.4 
 
Values represent mean ± SD (n=3) 
Note: a Conventional liposomes containing CF; b Invasomes containing CF; c Ethosomes containing CF;  
d Conventional liposomes containing mTHPC; e Invasomes containing mTHPC; f Ethosomes containing mTHPC; 
g Polydispersity index 
  
Table3: Results of skin penetration and deposition of CF into full-thickness human skin from 
different formulations with finite dosage application (10µl/cm2) after 12hr 
 
Formulati
ons 
Dose CF delivered (%) 
SC1-5 SC6-10 Epidermis Dermis Receptor  Total 
CF-PBSa 0.048±0.010 0.001±0.001 0.013±0.006 0.032±0.007 n.d.f 0.094±0.020 
CF-HEb 0.388±0.005 0.039±0.005 0.024±0.005 0.020±0.004 n.d. 0.471±0.010 
CF-CLc 0.070±0.009 0.009±0.005 0.029±0.014 0.029±0.011 n.d. 0.137±0.018 
CF-INSd 0.042±0.003 0.023±0.001 0.045±0.012 0.027±0.003 n.d. 0.136±0.006 
CF-ETSe 0.434±0.026 0.253±0.063 0.044±0.011 0.071±0.030 n.d. 0.802±0.090 
 
Values represent mean ± SD (n=3) 
Note: a PBS (pH7.4) containing CF (5.0mg/ml); b Hydroethanolic solution of ethanol and PBS pH 7.4 (9:11, v/v) containing 
CF (5.0mg/ml); c Conventional liposomes containing CF; d Invasomes containing CF; e Ethosomes containing CF; f Not 
detected 
  
Table 4: Results of skin penetration and deposition of mTHPC into full-thickness human skin 
from different formulations with finite dosage application (10µl/cm2) after 12hr 
 
Formulations Dose mTHPC delivered (%) SC1-5 SC6-10 Epidermis Dermis Receptor  Total 
mTHPC-ETa 1.500±0.113 0.040±0.013 0.047±0.007 n.d.f n.d. 1.580±0.120 
mTHPC-HEb 2.893±0.480 0.200±0.053 0.133±0.027 n.d. n.d. 3.220±0.487 
mTHPC-CLc 1.673±0.167 0.073±0.013 0.033±0.007 n.d. n.d. 1.780±0.180 
mTHPC-INSd 0.447±0.180 0.033±0.020 0.047±0.020 n.d. n.d. 0.527±0.160 
mTHPC-ETSe 1.253±0.053 0.040±0.020 0.060±0.020 n.d. n.d. 1.353±0.073 
 
Values represent mean ± SD (n=3) 
Note: a Ethanol solution containing mTHPC (1.5mg/ml); b Hydroethanolic solution of ethanol and PBS pH 7.4 (6:4, v/v) 
containing mTHPC (1.5mg/ml); c Conventional liposomes containing mTHPC (1.5mg/ml); d Invasomes containing mTHPC 
(1.5mg/ml); e Ethosomes containing mTHPC (1.5mg/ml); f Not detected 
  
Table 5: Results of skin penetration and deposition of CF into full-thickness human skin from 
different formulations with infinite dosage application (160 µl/cm2) after 12hr 
 
Formulation Dose CF delivered (%) SC1-5 SC6-10 Epidermis Dermis Receptor  Total 
CF-PBSa 0.020±0.007 0.006±0.003 0.005±0.001 0.009±0.002 n.d.f 0.041±0.013 
CF-HEb 0.361±0.050 0.044±0.005 0.011±0.001 0.015±0.005 n.d. 0.431±0.051 
CF-CLc 0.077±0.002 0.031±0.003 0.010±0.001 0.013±0.001 0.001±0.001 0.133±0.001 
CF-INSd 0.038±0.010 0.022±0.006 0.016±0.003 0.019±0.002 0.002±0.001 0.097±0.007 
CF-ETSe 0.682±0.041 0.397±0.100 0.138±0.012 0.123±0.037 0.021±0.004 1.361±0.152 
 
Values represent mean ± SD (n=3) 
Note: a PBS (pH7.4) containing CF (5.0mg/ml); b Hydroethanolic solution of ethanol and PBS pH 7.4 (9:11, v/v) containing 
CF (5.0mg/ml); c Conventional liposomes containing CF; d Invasomes containing CF; e Ethosomes containing CF; f Not 
detected 
  
Table 6: Results of skin penetration and deposition of mTHPC into full-thickness human skin 
from different formulations with infinite dosage application (160µl/cm2) after 12hr 
 
Formulations Dose mTHPC delivered (%) SC1-5 SC6-10 Epidermis Dermis Receptor  Total 
mTHPC-ETa 0.200±0.017 0.043±0.013 0.091±0.020 n.d.f n.d. 0.334±0.030 
mTHPC-HEb 0.364±0.013 0.026±0.009 0.010±0.006 n.d. n.d. 0.400±0.001 
mTHPC-CLc 0.228±0.044 0.016±0.005 0.011±0.002 n.d. n.d. 0.255±0.048 
mTHPC-INSd 0.113±0.009 0.010±0.003 0.008±0.003 n.d. n.d. 0.131±0.015 
mTHPC-ETSe 0.288±0.018 0.013±0.004 0.020±0.004 n.d. n.d. 0.322±0.012 
Values represent mean ± SD (n=3) 
Note: a Ethanol solution containing mTHPC (1.5mg/ml); b Hydroethanolic solution of ethanol and PBS pH 7.4 (6:4, v/v) 
containing mTHPC (1.5mg/ml); c Conventional liposomes containing mTHPC (1.5mg/ml); d Invasomes containing mTHPC 
(1.5mg/ml); e Ethosomes containing mTHPC (1.5mg/ml); f Not detected 
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Part Four 
Final Discussion 
 
As mentioned in the introduction section, the function of liposomes as skin drug 
delivery system varies with their type and composition, which has also been 
confirmed from all the results in this dissertation. Several kinds of liposomal systems 
were involved in this doctoral study, including conventional liposomes, deformable 
liposomes, invasomes, and ethosomes. As can be seen, for any given model drug, the 
composition diversity of its different carriers, lipid vesicles, could influence their 
physicochemical characteristics such as particle size, charge, morphology and bilayer 
elasticity, which in turn have a significant effect on the interaction between these 
vesicles and the skin and hence on their effectiveness as skin delivery systems. In 
addition, three model drugs with different lipophilicity were also involved in this 
dissertation, including Ferulic acid (logPo/w=1.51), Carboxyfluorescein (logPo/w= -1.5) 
and Temoporfin (logPo/w= 9.24). Thus, for a specific lipid vesicular system, the skin 
permeation or penetration and deposition behavior of its “cargo”, different model 
drugs, were significantly different. Hence, although the skin delivery of an active 
ingredient can be optimized by well-designed liposomal systems, it could be 
unfeasible to develop a universal liposomal formulation which would result in 
optimized skin delivery for all the active ingredients. In other words, the optimized 
skin drug delivery via liposomal systems should be designed and tested on a case by 
case basis.  
Furthermore, skin drug delivery via liposomal systems could involve several 
processes, including interaction between SC and lipid vesicles, partitioning of the 
drug from its lipid vesicular system to the skin and the following drug diffusion in the 
skin. Thus, the process of percutaneous absorption of model drug via liposomal 
systems as a whole could be influenced by not only the interaction between the 
liposomal system and skin but also the interactions between the liposome and drugs 
and ones between skin and drugs. And it is likely that these interactions might 
coincide since the lipid vesicles could interact with skin as well as the drug 
encapsulated.  
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1 Preparation and Characterization of Lipid vesicular systems 
All vesicular systems developed in publication 2 and 3 were prepared by a 
conventional rotary evaporation method combined with extrusion method. More 
detailed information could be found in the publication section. From the results on 
particle size distribution, the particle size of different lipid vesicular systems ranged 
from ~80nm to ~130nm, with all PDI < 0.2, indicating that all of them were highly 
homogeneous suspension systems. More specially, regardless of the model drug 
encapsulated, conventional liposomes showed the largest mean vesicle size. 
Ethosomes always showed the smallest mean particle size, which could be attributed 
to the incorporation of high amount of ethanol. Ethanol could probably reduce the 
membrane thickness due to the formation of a phase with interpenetrating 
hydrocarbon chains (Dubey et al., 2007). Moreover, the addition of ethanol in 
phospholipid vesicles imparts negative charge to the formulation (Touitou et al., 2000), 
which also explains there a net change flip over from conventional liposomes to other 
vesicles with fluid bilayers with the presence of ethanol. This modification of net 
charge of liposomal systems confers lipid vesicles some degree of steric stabilization 
and in turn lead to decrease in mean vesicle size (Jain et al., 2007). The reduction of 
particle size of Tween 80-based deformable liposomes when compared conventional 
liposomes could also be explained by inclusion of the surfactant involved (Elsayed et 
al., 2007a). In case of invasomes, lysophosphatidylcholine (LPC), as one of the 
components of NAT 8539, has a single hydrophobic chain and a polar head group and 
integrates spontaneously into membrane bilayers, is acting as a surfactant and creating 
a high positive curvature in membranes (Fuller and Rand, 2001). However, the 
inclusion of 1% (w/v) terpene mixture could lead to the increase of particle size 
distribution (Dragicevic-Curic et al., 2008), when compared with ethosomes and 
Tween 80-based deformable liposomes.  
From the results of Cryo-Transmission electron microscopy, regardless of model 
drugs encapsulated, the lipid vesicles had similar shapes and structures. The vesicles 
of the conventional liposomes seemed to be unilamellar and rarely bilamellar, almost 
spherical and oval in shape, and some detected oligolamellar vesicles. In the case of 
Tween 80-based deformable liposomes, the vesicles were also mostly unilamellar. In 
the case of invasomes, the vesicles seemed to be almost unilamellar and bilamellar, 
but the percentage of deformed vesicles increased in comparison to other liposomal 
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structures. Regarding ethosomes, the vesicles appeared to be homogenously 
unilamellar. 
The ζ-potential is related to the charge on the surface of the lipid vesicle which 
influences both vesicular properties such as physical stability and skin vesicle 
interactions. The electrostatic repulsive forces can prevent the dispersed particles 
having surface charges of the same sign from approaching each other. For dispersed 
particles below of 1µm, moderate physical stability is achieved when the ζ-potential is 
between ±30 and ±60mV, and good to excellent physical stability is achieved when 
the ζ-potential is between ±60 and ±100mV (Rungseevijitprapa et al., 2009). 
Invasomes, regardless of model drug encapsulated, showed a ζ-potential about -40mV. 
Ethosomes containing ferulic acid (Publication 2) showed a ζ-potential about -30mV, 
while ethosomes containing CF or mTHPC showed a ζ-potential about -80mV. Thus, 
invasomes and ethosomes developed in this doctoral study were well stabilized 
against interparticle attraction or coagulation. On the other hand, conventional 
liposomes and Tween 80 based deformable liposomes had low ζ-potentials and tend to 
be more sensitive to coagulation. However, all liposomal formulations for in-vitro 
penetration/permeation study were freshly prepared in order to avoid instability of 
lipid vesicular systems.  The effect of surface charge of liposomes on the drug 
penetration has not been fully understood so far. Some researchers support the theory 
that the positive charges on the surface of liposomes could bind to negative charges of 
the SC enhancing thereby the drug penetration/permeation through the skin (Katahira 
et al., 1999; Song and Kim, 2006). However, other studies found that permeation of 
drugs through the skin is promoted by negatively charged vesicles (Ogiso et al., 2001; 
Sinico et al., 2005). According to the best of our knowledge, the surface charge of the 
vesicles will not only play a role on the interaction between skin and vesicles but also 
might contribute to the drug release from the vesicles. The drug release from vesicles 
in the stratum corneum is an important step which will affect transdermal 
flux(Honeywell-Nguyen and Bouwstra, 2003). The rate and amount of released drug 
is a balance between two factors: (1) drug affinity to vesicles, and (2) drug solubility 
in lipids of the stratum corneum (Honeywell-Nguyen and Bouwstra, 2003). The 
results of the pilot experiment of publication 2 revealed that the flux of FA from 
negatively charged ethosomes is somewhat higher than from positively charged 
ethosomes, but without any significant difference. Since both the pKa1 of FA (4.52 
(Erdemgil et al., 2007)) and pKa of CF (6.3 (Nicole et al., 1989)) are below 7.4, they 
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are negatively charged at pH 7.4. Therefore we suggested that both of them could be 
retained in the positively charged vesicles, which in turn influences their skin 
penetration or permeation. Thus, we also preferred to prepare the negatively charged 
lipid vesicles containing mTHPC for comparison. For the effect of positively charged 
liposomes and neutralized liposomes on the skin penetration and deposition of CF and 
mTHPC is investigated in future. 
2 Human Skin Preparation  
As mentioned in the introduction section, when a skin drug delivery system is 
applied topically, two principle absorption routes are involved, including the 
transepidermal route, where the drug delivery system interacts with or diffuses 
through stratum corneum, and transfollicular route, where they interact with or diffuse 
through the follicles. Female human abdominal skin tissue from plastic surgery was 
used in publication 3. From literature (Starcher et al., 2005), the hair follicles of 
human are surrounded by an elastic fiber network, which connects the follicles to each 
other. The fibers not only surround the hair follicles but also lie as parallel fibers 
throughout the entire dermis. This different pattern of elastic fibers suggests an 
important role in the elasticity of skin. If the skin is excised, the elastic fibers 
surrounding the hair follicles contract, which possibly leads to a significant reduction 
of the follicular penetration pathway (Patzelt et al., 2008). Moreover, other factors 
concerning the reduced follicular penetration must also be taken into consideration, 
such as loss of humidity and the absence of blood flow in excised skin. These aspects 
presumably contribute additionally to the differences in the penetration pathways to a 
certain extent (Patzelt et al., 2008). Furthermore, in publication 2, the stratum 
corneum/epidermis (SCE) membranes were prepared by a heat separation technique 
and applied with in vitro permeation study. In this skin model, intrafollicular route 
could be involved. However, at in vivo situation of human skin as mentioned in the 
introduction section, hair follicular route could be highly lipophilic because of 
presence of sebum, while the follicle route in this skin model could be a hydrophilic 
one due to the absence of sebum. Moreover, it remains unexplored and unclear that 
how different lipid vesicular systems can influence the follicular route contribution of 
drug permeation and deposition.  
All of these problems mentioned could be investigated in future study. In this 
dissertation, only transepidermal route would be discussed at length.  
Part Four                                                     Final Discussion 
101 
 
3 The Interaction among conventional liposomes, Model drugs and 
skin  
From the results presented in publication 2 and publication 3, when compared 
with deformable liposomes or ethosomes, conventional liposomes cannot deliver 
considerable much amount of model drug into skin deep layer, such as epidermis, 
dermis as well as the receptor phase (subcutaneous layer), they can significantly 
enhance model drugs deposition in the stratum corneum layer. This suggested that 
conventional liposomes could not be a suitable approach for transdermal delivery of 
drugs but could be relatively useful for dermal delivery. The involved mechanism of 
action of conventional liposomes could fall into one of three categories (reviewed in 
publication 1), including the intact vesicular skin penetration, the penetration 
enhancing effect, and vesicle adsorption to and/or fusion with the stratum corneum 
(El Maghraby et al., 2006).  
The first possible mechanism that intact conventional liposomes can penetrate 
across the skin was received with skepticism. Realistically, any phospholipid vesicles 
can cross the skin barrier only through hydrophilic pathways (intercellular route) and 
they have to possess two capabilities: the colloid-induced opening of the very narrow 
(~0.4 nm) gaps between cells in the barrier to pores with a diameter greater than 30 
nm, and self-adapting to the size of 20 to 30 nm without destruction (Cevc, 2004). 
Obviously, conventional liposomes fall short of these prerequisites. As a result, it is 
almost impossible for large conventional liposomes to penetrate the densely packed 
SC in great numbers. The skin permeation or penetration results in publication section 
also suggested that the penetration of intact conventional liposomal vesicles may be 
not a reasonable, or at least not a predominant, mechanism for improved skin drug 
delivery.  
The second mechanism, penetration enhancing effect, is that conventional 
liposomal lipids may act as penetration enhancer, thereby loosening the lipid structure 
of the SC and promoting an impaired barrier function (Kirjavainen et al., 1999). From 
the results of publication 3, it can be recognized that the effectiveness of this 
penetration enhancing effect of conventional liposomes could depend on the 
lipophilicity of drug molecule. From results of publication 3, with same conventional 
liposomal formulation, most of mTHPC (both finite and infinite dose application) was 
found in SC top layer, while relatively much more percentage of CF (also both finite 
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and infinite dose application) could be delivered into skin deep layers compared with 
their control group, respectively. There three reasonable explanation. First, for 
hydrophilic molecules such as CF owing to their low partition coefficient and 
relatively slow diffusion through stratum corneum, they tend to be more enhance-able 
and hence would show a dramatic increase in permeation or penetration as well as 
deposition in skin deep layers via conventional liposomes. In addition, this 
penetration enhancing effect just increases the partitioning of model drugs into the 
lipophilic SC but does not really increase the partitioning of model drugs from the SC 
into the less lipophilic epidermis. This means that permeability of lipophilic 
penetrants such as mTHPC is limited by partitioning from lipophilic SC into 
hydrophilic epidermis. Another possible reason why most of mTHPC (both finite and 
infinite dose application) was found in SC top layer is that mTHPC possibly could 
interact with SC, specifically with keratin or lipids in corneocytes. Thus, mTHPC 
were bottled up in SC. This phenomenon is referred to as the Stratum Corneum 
reservoir effect (Vickers, 1972). Other drugs such as corticosteroids also have this 
phenomenon (Lu and Flynn, 2009).  
Another mechanism, vesicle adsorption to and/or fusion with the stratum 
corneum, is that topical application of conventional liposome could result in the 
formation of lamellae and rough structures on skin surface, which could increase the 
skin hydration and in turn increase the driving force for permeation of liberated 
molecules. However, the collapse of vesicles on skin surface may form an additional 
barrier, reducing the permeation of hydrophilic molecules encapsulated in the 
vesicular aqueous core (Elsayed et al., 2007b). This could be responsible for the 
difference between CF and mTHPC on their skin distribution ratio shift and change 
when comparing an infinite dose with a finite dose application in the case of 
conventional liposome (publication 3).  
In addition, one thing could be important for hydrophobic drug such as mTHPC, 
which is that the solubility of mTHPC in conventional liposomes was increased 
definitely. In publication 3, the concentration of mTHPC in all liposomal systems is 
1.5mg/ml, while the aqua solution of mTHPC is not available since its extremely low 
solubility in water. When liposomal systems interact with skin, mTHPC encapsulated 
would be released into stratum corneum. This point could contribute quite a lot to skin 
delivery of mTHPC via conventional liposomes. 
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4 The Interaction among Deformable Liposomes/Invasomes, Model 
drugs and Skin  
When compared with conventional liposomes, deformable liposomes, including 
Tween 80-based deformable liposomes and invasomes showed a better permeation 
ferulic acid across the stratum corneum and epidermis membrane (Publication 2), or 
invasomes led to relatively higher drug accumulations in skin deep layers (including 
epidermis and dermis as well as the receptor phase) in the case of both CF and 
mTHPC (Publication 3). Thus we suggested that deformable liposomes, compared 
with conventional liposomes, could be more effective as a transdermal drug delivery 
system (Reviewed in publication 1).  
There are two possible mechanisms responsible for the enhanced skin drug 
delivery via deformable liposomes (Honeywell-Nguyen et al., 2003; Honeywell-
Nguyen and Bouwstra, 2003). First, invasomes may act as drug carrier systems by 
which intact vesicles can enter the SC carrying vesicle-bound drug into or across the 
skin. Water gradient or xerophobia, which is the tendency to avoid dry surroundings 
of water-“loving” phospholipids, was regarded as the driving force for deformable 
liposomes entering the skin by this mechanism (Cevc and Blume, 1992). However, 
the water gradient across the skin may not be linear, consequently, as a result of the 
osmotic force such vesicles will not penetrate beyond the level of the lowest layers in 
the SC (Honeywell-Nguyen and Bouwstra, 2003). Consequently, the drugs will be 
released first from such vesicles and then penetrate alone to skin deep layers or to 
reach the systemic circulation (Bouwstra and Honeywell-Nguyen, 2002). Therefore, 
non-occlusive application is necessary for the enhanced skin drug delivery based on 
deformable liposomes by this mechanism. As mentioned above, when infinite dose 
applied, with a thick formulation liquid layer formed covering on the skin surface, 
deformable liposomes such as invasomes could lose its penetration driving force 
because of the disappearance of the trans-epidermal osmotic gradient in this 
application mode. Hence, less percentage of CF and mTHPC could be delivered into 
skin deep layers with infinite dose application (Publication 3). Second, deformable 
liposomes may also act as penetration enhancers, whereby the vesicle lipid bilayers 
interact with the SC and subsequently modify the intercellular lipid lamellae. 
Similarly, from the results presented in publication 3, penetration enhancement of 
model drugs by this mechanism could be influenced by the lipophilicity of model 
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drug. Specially, for hydrophilic drugs such CF, the penetration enhancing effect could 
play a more important role in the enhanced skin delivery than in the case of lipophilic 
drugs. The possible reasons have already been discussed above. In fact, one of the two 
mechanisms might predominate according to the physicochemical properties of the 
drug considered (Elsayed et al., 2007b).  
In addition, Tween 80-based deformable liposomes (10% of ethanol involved 
inside) showed a better permeation profile and skin deposition of ferulic acid than 
hydroethanolic solution (Publication 2). This could be explained by the synergistic 
effect of phospholipids and ethanol, which is that ethanol and phospholipids applied 
together have a synergistic effect on fluidizing the intercellular SC lipids, which 
results in an enhanced penetration of chemicals (Verma and Fahr, 2004).  Moreover, 
the enhanced skin delivery of ferulic acid via invasomes when compared with 
hydroethanolic solution (Publication 2) as well as the enhanced skin delivery of CF 
via invasomes when compared with hydroethanolic solution (Publication 3) could also 
support a similar synergistic effect of phospholipids, terpenes and ethanol. However, 
improved skin delivery of mTHPC via invasomes was not observed when compared 
with hydroethanolic solution. The main possible reason is that mTHPC is highly 
hydrophobic, the incorporation of water in ethanol will increase its thermodynamic 
activity compared with pure ethanol solution containing the same concentration of 
mTHPC. For the lipid vesicular systems containing mTHPC such as invasomes 
prepared in publication 3, even though high water amounts are involved, entrapment 
of mTHPC in the lipid bilayers, in fact, solubilizes mTHPC. Hence, the 
thermodynamic activity of mTHPC of these systems is not equally increased 
compared with mTHPC hydroethanolic solution, which explains why mTHPC 
hydroethanolic solution showed the better potential of improving mTHPC skin 
delivery than all lipid vesicles including invasomes. From all these results presented 
in publication 2 and publication 3, we support the hypothesis that some of the 
invasomes were fragmented during their penetration through the SC, while some of 
the small and deformable invasomes could have penetrated to the deeper SC layers 
intact. 
In short, the mechanism of action of deformable liposomes or invasomes is not 
clearly and completely understood, and it should be further investigated and 
confirmed with involving more model drugs and novel technologies.  
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5 The Interaction between Ethosomes, Model drugs and Skin  
As we can see from the results presented in publication section, Ethosomes 
showed a better permeation profile and a higher skin epidermis deposition of ferulic 
acid than all other lipid vesicular systems (Publication 2). Ethosomes also delivered 
more percentage of CF into skin deep layers (epidermis and dermis, as well as 
receptor phase) than all other lipid vesicular systems (Publication 3). Interestingly, 
unlike deformable liposomes, ethosomes are able to improve the skin delivery of 
drugs both under occlusive and non-occlusive conditions (Elsayed et al., 2007a; 
Lopez-Pinto et al., 2005; Paolino et al., 2005; Touitou et al., 2000), depicting a 
different mechanism of action for ethosomes (Reviewed in publication 1). 
High concentration of ethanol (45%, v/v) involved in the ethosomal system 
(Publication 2 and 3) must be responsible for the enhanced skin drug delivery 
described. Ethanol is a well-known permeation enhancer (Williams and Barry, 2004). 
The penetration enhancing effect of ethanol can be attributed to two effects: (a) “Push 
effect”: increased thermodynamic activity due to evaporation of ethanol and improved 
solubility of solute in this study; (b) “Pull effect”: ethanol can interact with 
intercellular lipid molecules in the polar head group region, thereby increasing their 
fluidity and decreasing the density of the lipid multilayer, which results in an increase 
in membrane permeability. Ethanol is also supposed to extract the SC lipids (Bach and 
Lippold, 1998) lowering thereby the barrier function of the SC.  
Furthermore, ethosomes showed a better permeation profile and skin deposition 
of ferulic acid than both ethanol solution and phospholipid ethanol solution 
(Publication 2). Also, ethosomes delivered much more CF into skin deep layers, 
including epidermis, dermis and receptor phase than hydroethanolic solution 
(Publication 3). These results support that a synergistic mechanism between ethanol 
and lipid vesicles could facilitate drug delivery to the deeper skin layers or across the 
skin (Dayan and Touitou, 2000; Elsayed et al., 2006; Touitou et al., 2000). More, 
ethanol could impart fluidity to the vesicle's bilayers, which in turn facilitates vesicles 
skin permeation. Furthermore, ethanol has a tendency to mix with lipids as well as 
water (Panchagnula et al., 2005), with increasing the partition of liposomal particles 
into skin. Thus it can act as a “blending” agent for lipid vesicles with increasing their 
distribution in skin (Panchagnula et al., 2005). The ethanol effects can be followed by 
the interaction between ethosomal vesicles and the skin. The ethosomal vesicles may 
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also behave as deformable liposomes and can interact with the skin barrier to “forge” 
penetration or permeation pathways by itself in the highly organized SC and finally 
release drug at various points along the penetration pathway as well as in deep skin 
layers (Elsayed et al., 2007b). 
From the discussion above, we suggest that ethanol and its concentration are key 
points which influence the physicochemical characteristics of the ethosomes and in 
turn affect the ability of ethosomes as skin delivery systems.  In fact, the effect of 
concentration of ethanol on skin drug delivery ability of ethosomes has been 
investigated in pilot experiments of publication 2 (data not involved in this 
dissertation). Form the results of this pilot experiment, 45% of ethanol in the 
ethosomal system showed the best potential for enhanced skin delivery of ferulic acid. 
For comparison, this concentration was also applied in publication 3. However, for the 
purpose of optimum skin delivery of different model drugs, optimal concentration of 
ethanol in ethosomes could be varied depending on the physicochemical property of 
model drug. Thus, effective ethosomes for different model drugs could be also 
designed and test on a case by case basis. For instance, from the results presented in 
publication 3, ethosomes didn’t show a significantly enhanced skin delivery of 
mTHPC compared with ethanol solution and hydroethanolic solution. Two possible 
reasons have been discussed above. Briefly, first, since mTHPC can be encapsulated 
in the ethosomal vesicles bilayers, ethosomes could also be the solubilization matrix 
of mTHPC. Thus the thermodynamic activity of mTHPC in ethosomes is not equally 
increased compared with mTHPC hydroethanolic solution. Second, the ethosomes 
containing mTHPC developed in publication 3 didn’t show a satisfying and promising 
skin penetration enhancing effect for mTHPC compared with its hydroethanolic group. 
From this point of view, the composition of ethosomes need be optimized further. 
Moreover, even with same composition, different vesicular structure could be 
developed by different preparation method. Therefore, better designed lipid carrier 
systems especially for mTHPC could be developed in future. 
6 The Effect of Application mode on Skin Drug Delivery 
The compositions of these formulation change due to penetration into the skin or 
evaporation of volatile components. These changes depend on the amount of liposome 
applied and occlusion conditions. Many studies have employed non-occluded 
conditions, but the application amount was varied. The amounts of formulation have 
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ranged from 10μL/cm2 (Dragicevic-Curic et al., 2008; Verma and Fahr, 2004) to 
1.5mL/cm2 (Elsayed et al., 2007a). These differences may be related to variations in 
the observed effects of lipid vesicular systems, but there have been few reports aiming 
to clarify the effects of dose on lipid vesicular systems penetration. 
In publication 3, a comparison of an infinite dose and a finite dose under non-
occlusive application for both CF and mTHPC revealed that the total amount of both 
of them delivered into skin were significantly increased when an infinite dose applied, 
but to a significantly different extent depending on the lipophilicity of model drugs. 
There could be two possible reasons responsible for this. The first one is that the 
increased skin hydration effect rooted from a thick liquid formulation layer covering 
on the skin surface formed by an infinite dose applied in donor compartment. This 
increased tissue hydration appears to increase transdermal delivery of both 
hydrophilic and low lipophilic compounds such as CF due to an increase in partition 
into the skin of drugs but not for highly lipophilic drug such as mTHPC. Another 
possible reason could be the different molecular mechanisms by which the diffusion 
through the stratum corneum of CF and mTHPC is acting. More specifically, with an 
infinite dose of formulation applied on the skin, the modification of the micro-
structure of SC could be increased compared with a finite dose applied. This will 
facilitate the skin penetration and deposition of CF because the limiting step for skin 
penetration of CF is its partitioning into SC from the formulation. However, due to the 
limiting step for mTHPC being the partitioning from the SC into the less lipophilic 
epidermis, the augmented modification of the micro-structure of SC by an infinite 
dose could not result in the same enhancing effect for mTHPC as for CF.  
In short, application mode, including infinite dose application and finite dose 
application, not only had a direct action on the drug skin penetration and deposition, 
but also could affect the degree of hydration of the SC and the possible mechanism of 
some lipid vesicular system which in turn influence the drug skin distribution.  
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Part Five 
Summary 
 
Skin is the largest organ of the human body and offers a glorious route for 
delivering drugs because skin drug delivery brings forth many attractive advantages 
over other routes of administration. On the other hand, however, skin is also an 
excellent biological barrier, which imposes physicochemical limitations to the type of 
permeants which can traverse it. Over the past decades, numerous studies have been 
performed to overcome the problems associated with skin delivery and also a number 
of novel skin delivery systems and approaches have been developed. Among these 
novel techniques, lipid vesicular systems may offer a promising strategy for 
improving skin drug delivery.  
In this doctoral dissertation, different lipid vesicular systems including 
conventional liposomes, Tween 80-based deformable liposomes, invasomes and 
ethosomes were prepared and characterized in order to improve the skin delivery of 
ferulic acid, which is a traditional Chinese medicine exhibiting a wide range of 
therapeutic effects against various diseases. As can be seen from in vitro permeation 
and deposition study, skin permeation flux and skin deposition of ferulic acid could be 
significantly improved by well developed lipid vesicles. Moreover, different lipid 
vesicular systems containing another two model drugs, Carboxyfluorescein and 
Temoporfin, were developed and characterized in order to evaluate and compare the 
influence of different lipid vesicular systems on their skin penetration and deposition 
behaviors. In addition, different application modes, including application of finite 
dosage and infinite dosage, were involved and investigated. In vitro penetration and 
deposition studies revealed that different lipid vesicular systems could possibly 
provide variable skin drug delivery effects according to their composition, entrapped 
drug as well as application mode applied.  
Also, a variety of possible mechanisms have been discussed in details for the 
enhanced skin delivery of drugs from different lipid vesicles, implying that the skin 
drug delivery via lipid vesicular systems could be influenced by the interaction not 
only between the liposomal system and skin but also  between the liposome and drugs, 
and between skin and drugs.   
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Zusammenfassung 
 
Die Haut ist das größte Organ des menschlichen Körpers und bietet 
Möglichkeiten für die Aufnahme von Medikamenten. Der Haut-Arzneistoff-Transfer 
besitzt viele attraktive Vorteile gegenüber anderen Arten der Darreichung. Auf der 
anderen Seite ist die Haut aber auch eine ausgezeichnete biologische Barriere, die der 
Permeation von Stoffen physikalisch-chemische Grenzen setzt. In den vergangenen 
Jahrzehnten wurden zahlreiche Studien durchgeführt, um diese Probleme zu 
überwinden und neue Ansätze für Haut-Transfer-Systeme zu entwickeln. Unter diesen 
neuen Techniken stellen vesikuläre Lipidsysteme eine vielversprechende Strategie zur 
Verbesserung der Haut-Arzneistoff-Transfers dar. 
In dieser Dissertation wurden verschiedene vesikuläre Lipidsysteme, 
konventionelle Liposomen, Tween 80-basierte verformbare Liposomen, Invasomen 
und Ethosomen, hergestellt und charakterisiert, um den Haut-Transfer von 
Ferulensäure zu verbessern. Die Ferulensäure wird in der traditionellen chinesischen 
Medizin angewendet und besitzt ein breites Spektrum an therapeutischen Wirkungen 
gegen verschiedene Krankheiten. Wie in-vitro-Permeations- und Depositionsstudien 
zeigten, können der Transfer durch die Haut und die Einlagerung von Ferulensäure in 
die Haut durch gut entwickelte Lipidvesikel verbessert werden. Darüber hinaus 
wurden verschiedene vesikuläre Lipidsysteme mit zwei weiteren Modellarzneistoffen, 
Carboxyfluorescein und Temoporfin, entwickelt und charakterisiert, um den Einfluss 
verschiedener Lipidvesikelsysteme auf Permeation und Deposition zu beurteilen. 
Darüber hinaus wurden verschiedene Applikationsmodi, einschließlich der finiten und 
infiniten Dosierung, entwickelt und untersucht. In-vitro-Penetrations- und 
Depositionsstudien zeigten, dass unterschiedliche vesikuläre Lipidsysteme 
entsprechend ihrer Zusammensetzung, dem eingeschlossenen Arzneistoff sowie des 
Applikationsmodus variable Haut-Arzneistoff-Transfer-Effekte erzielen. 
Eine Vielzahl möglicher Mechanismen für die Verbesserung des Haut-
Arzneistoff-Transfers mit verschiedenen Lipidvesikeln wurde im Detail diskutiert. 
Diese legen nahe, dass der Haut-Arzneistoff-Transfer nicht nur durch die Interaktion 
zwischen den Liposomen und der Haut sondern ebenfalls durch die 
Wechselwirkungen zwischen Liposom und Arzneistoff und zwischen Arzneistoff und 
Haut beeinflusst wird.  
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